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The adaptive immune response consists of interplay between CD4 T cells, CD8 T cells, 
and B cells which function in control of pathogen in the host. T cells responding via their TCR 
express cytokines and costimulatory molecules that support direct effector activity and also 
promote high-affinity antibody generation through augmenting of B cell responses. However, the 
molecular components that contribute T cell function to balance viral control and the potential 
for host damage are incompletely understood. In this work, we establish a role for the adaptor 
molecule CD2AP in modulation of CD4 T cell responses to chronic LCMV infection in mice 
though the generation of T Follicular Helper cells.  We find that CD2AP modulates TCR 
signaling during viral infection and its deletion augments the germinal center response and 
generation of neutralizing antibodies. CD8 T cells are subject to negative regulation via 




determine the functions of PD-1 during different stages of chronic viral infection which reveals 
an important role in maintenance of durable immunity. Treating mice infected by a chronic strain 
of LCMV with PD-1 blockade at the peak of viremia does not cause fatal immunopathology, but 
eventually resulted in disruption of lymphoid architecture and a reduction in the CD8 T cell 
response. Furthermore, transient blockade of type-I interferon completely prevented death of 
LCMV-infected mice treated with PD-1 blockade at the time of infection, intriguingly a 
combination of the transient blocking IFNAR signaling and delayed PD-1 blockade, which alone 
would compromise antiviral immunity, accelerated viral clearance without causing 
immunopathology. These results indicate that harnessing CD8 T cells at early stages of chronic 
viral infection in paradoxically benefits long-term immunity and eventually results in enhanced 
































1.1 General Aspects of Immunity to Pathogens 
A central feature of all life is the potential for invasion by parasitic entities including but 
not limited to viruses and bacteria 1. Evidence of constant attack exists in genomes which harbor 
active and inactive selfish genetic elements and the evolved genetic machinery to restrict their 
spread 2. These conflicts have persisted through biological time and have resulted in so-called 
“evolutionary” arms races to aid in survival and fecundity of the parasite or host 3. In higher 
order metazoans, highly unique and novel molecular, cellular, and physiological entities have 
evolved to provide protection to the host from microbial entities whose presence has the potential 
to cause survival disadvantages. This physiologic process of protection is known as an 
organisms’ “immune system”. 
We now focus on features of the immune system present in animals phylogenetically 
above jawed fish. This distinction is made as a highly anticipatory repertoire to foreign entities 
that is not germline encoded exists – the adaptive immune system {Flajnik:2010ii}. We thus 
make a broad categorization of the immune system between an “innate” and an “adaptive” 
component. The innate immune system can be loosely defined as defense mechanisms that are 
germline encoded 4. The innate immune system which is responsible for control of >95% of 
encountered pathogens is inclusive of physical barriers (skin, mucous layers of the gut), the 
complement pathway, and the more well-studied cells of hematopoietic origin including those of 
the myeloid lineage (Macrophage, Monocyte, Dendritic Cells, and granulocytes). These cells 
form significant part of innate immune system by recognizing common pathogenic molecular 
patterns and or damage associated molecular patterns and inducing specific responses. These 




effector products to both directly inhibit and facilitate the recruitment of other cells in response 
to pathogenic stimuli.  
While the innate immune system recognizes relatively non-specific moieties present in 
microbes, the adaptive immune system is much more specific. Specificity is achieved through 
germline rearrangements at specific loci whose gene products are uniquely expressed on 
individual cells. The cells that engage in this process during their development include B and T 
lymphocytes; each cell expresses a unique B cell receptor (BCR) or T cell receptor (TCR) 
reflecting this germline rearrangement, known as V(D)J recombination 5.  The germline 
recombination generates a repertoire of lymphocytes within a host to recognize pathogens with 
virtually indefinite breath and incredible specificity. The BCR of B cells can be secreted in the 
form of an antibody which carries a unique binding site for antigen allowing for recognition any 
molecular moiety. However, the TCR of T cells can only recognize antigen in the form of 
peptide or lipid complexes presented on the cell surface by MHC or MHC-like molecules. 
Together, one can think of the B cells as providing recognition and effector capabilities in the 
extracellular compartments, while T cells recognize intracellular components.  
 
1.2 Components of the Adaptive Immune Response 
The ultimate products of the adaptive immune system are the generation of high-affinity 
potentially neutralizing antibodies, and the generation of effector antigen-specific CD4+ and 
CD8+ T cells. The generation of high titers of antibody in the serum bind to antigen which 
facilitates elimination from the host by a variety of mechanisms described elsewhere. Effector T 




and can either directly mediate cytotoxicity, and secrete soluble mediators such as cytokines or 
chemokines which promote clearance of pathogen. The next section will describe how the 
adaptive immune response is initiated.   
Following V(D)J recombination and development in the bone marrow, B cells reside in 
secondary lymphoid organs in areas known as B cell follicles or in an adjacent structure known 
as the marginal zone. B cells remain in a naïve state until encounter with antigen where they 
become partially activated and then migrate to the T-B border and receive CD4+ T cell help. 
Following these initial activation events, antigen specific B cells can form germinal centers, a 
specialized structure within the B cell follicle where B cells undergo somatic hypermutation and 
affinity maturation 6. A key player in this process is selection mediated by a specialized subset of 
CD4 T cells, known as T Follicular Helper cells, which form the rate-limiting step in the GC 
reaction 7. The result of this process generates memory B cells and plasma cells which actively 
secrete antibody in the bone marrow.  
 T cells have a more specialized developmental process that is initiated by precursors in 
the bone marrow, and then is completed in a specialized organ, known as the thymus. This 
process occurs as T cells can only recognize antigen in the context of MHC, a highly 
polymorphic locus. Given that the TCR and MHC loci are unlinked, this poses an interestingly 
problem. In the thymus, committed progenitors undergo V(D)J recombination at the TCR locus, 
a sequential steps of positive selection, and negative selection to remove potentially auto-reactive 
cells to MHC complexes, effectively generating and pruning potential TCRs 8.  
Following their development in the thymus, naïve T cells continuously traffick between 




peptide:MHC complexes presented on antigen presenting cells (APCs), T cells become activated 
undergo clonal expansion and effector differentiation commensurate the cytokine milieu present 
in the microenvironment.  
A key distinction is made between CD4+ T cells which recognize MHCII and CD8 T 
cells which recognize MHC I. MHCII is expressed on professional antigen presenting cells, 
including B cells, and thus forms the molecular basis for specificity in antigen specific B cell 
mediated help.  MHCI however is expressed on all nucleated cells, and are thus potential targets 
for CD8 T cells. In the context of infection, local chemokines recruit T cells into the tissue non-
specifically, when effector T cells recognize cognate peptide:MHC either on the surface of APCs 
for CD4 T cells or infected non-hematopoietic epithelial, or mesenchymal cells for CD8 T cells 
they release additional cytokines such as IFN-g and TNF-a.  
1.3 Signaling Modalities and Mechanisms Governing T cell Function 
An overview of T cells has been given in the previous sections, however, the molecular 
underpinnings the regulate and modulate their function in specific contexts will be described 
herein. Specific focus will be placed upon the cellular basis T cell activation in lymphoid organs 
and the interplay between APCs, antigen, and cytokine milieu. In addition, the biochemical 
signal transduction pathways occurring within T cells upon activation and the ultimate global 
transcriptional changes that “program” differentiation will be discussed.  
A major driver of T cell activation is recognition of antigen by pMHC complexes by the 
TCR. The nature of what exactly is required for “activation” is subject to significant modulation 
by the environment; antigen dose, quantity, and duration can play a significant role in whether T 




costimulatory signals and adhesion molecules that strengthen T cell-APC interactions 10. 
However, these do not dictate necessarily whether a response will occur or not; this is largely 
determined by presence of antigen in lymphoid organs for sufficient periods of time9. 
The TCR is composed of an alpha and beta chain which form a heterodimer in complex 
with CD3 subunits which carry ITAM motifs required for signal transduction 11. Upon TCR 
binding to pMHC, the kinase Lck is recruited via the CD4 or CD8 co-receptors to phosphorylate 
the CD3 ITAMs. This initiates a complex cascade of signal transduction events including ZAP-
70 phosphorylation of LAT which recruits additional signaling and adaptor molecules such as 
SLP-76, Grb2. A key focal point of these proximal signaling pathways is the activation of 
PLCg1 which converts PIP3 into IP3 and DAG. IP3 promote Calcium Flux and activation of 
NFAT while DAG activates the MAPK, and NF-kB pathways. Ultimately the activation of these 
pathways converges in the nucleus to drive transcriptional changes required for T cell clonal 
expansion, and differentiation into effector T cells.  
While the key molecular players leading from transduction of signal from outside the cell 
to the nucleus are relatively well-defined how the TCR can discriminate affinity to functional 
output, how the TCR signal is properly terminated, and the roles of a variety of other accessory 
scaffold and pathways contribute to T cell function remain unclear.  In addition, much of what 
we know about TCR signal transduction is derived from in vitro experiments, or administration 
of model antigens to specific TCR-transgenes with many of end readouts for activity being initial 
proliferation or cell-surface marker expression. In the context of a full immune response with T 
cell activation in lymph node and repeated stimulation of CD4 T cells by B cells in GC reaction, 
or in the context of persistent antigen in either chronic infection or tumors, how the TCR remains 




Broadly, the regulation of TCR signaling can be divided into two categories, intrinsic cell 
biological regulation of the TCR and its signaling components via post-translational 
modifications, degradation, endosomal sorting, recycling, and direct phosphatase activity or via 
extrinsic signaling from other cell surface molecules in trans12. While these are somewhat 
related, an important distinction is that the T cell and consequently activity of the TCR can be 
regulated by factors present in the tissue microenvironment.  
The TCR is well-known to undergo cycles of internalization and degradation, combined 
with recycling to both terminate the TCR signal 13.  How this process is regulated is relatively 
unclear, and factors that modify this process could play a significant role in the immune response 
as aberrant TCR signaling has physiological consequences. In addition, a variety of direct gene 
products induced by the TCR include phosphatases, and phosphatase activity increases following 
TCR stimulation to terminate signal.  
 Following T cell activation numerous cell surface receptors are expressed that have both 
co-stimulatory and co-inhibitory functions 10,14. Namely, PD-1 has a strong negative effect on T 
cell signal transduction predominantly through CD28, but also directly through the TCR15. PD-1 
sits on top of the hierarchy of inhibitor receptors which also include CTLA-4, Tim-3, LAG-3, 
CD160, 2B4, and TIGIT, which effectively inhibit T cells via relatively undefined mechanisms. 
Conceptually, the ligation of these receptors allows for tuning of TCR signal according to 
microenvironmental cues, which is highlighted by several lines of evidence suggesting loss of 
these receptors result in autoimmune phenotypes 16,17. Thus, T cells are subject to strong negative 
feedback through a variety of mechanisms; these can inhibited, directly, or indirectly via 




examples illustrate the potential for complexity in the execution of the T cell adaptive immune 
response and how certain factors can modulate the outcome of infection or tumors. 
1.4 T cells in the Fray: Effector Subsets and Impact on Host Physiology  
While naïve T cells each possess a unique TCR, functionally they can be considered the 
same, however, following activation, the resulting effector cells are well-known to exhibit 
significant heterogeneity. This heterogeneity is reflected primarily on differential cell surface 
receptor expression, transcription factor expression, and certain ex vivo functional capabilities18. 
Ultimately, one is interested in understanding how this heterogeneity contributes to a functional 
immune response and how this heterogeneity develops. The sections below will describe this 
phenomenon in some detail first for CD4+ T cells and then for CD8+ T cells. 
 The functional differentiation of CD4 T cells is primarily conceptualized in the T helper 
subset paradigm of TH1, TH2, and TH17 cells that are induced following exposure to so-called 
“lineage-specific” cytokines 19. These cytokines can be generalized to promote the differentiation 
of cells appropriate to the insulting pathogen, and consequently their effector functions are 
tailored to the needs of the host. It should be noted many of these studies are derived for in vitro 
experiments and it appears there is considerable overlap in transcription factor expression and 
cytokine secretion between these subsets. Perhaps, a more conservative view, is that these 
transcription factors directly promote specific cytokine secretion.  
 Another paradigm which to view CD4 helper subsets is a functional one within the 
confines of a given infection. Taking a viral infection as an example, it is well-established the 
generation of an affinity matured antibody response requires CD4 T cells, specifically help 




stimulatory signaling to B cells in addition to receiving soluble cytokine signals such as IL-21, 
and others for inducible class switching 7. In addition, CD4 T cells provide support in the form of 
cytokines such as IL-21 or IFN-g to CD8 T cells via or indirectly via DC licensing, and to 
macrophages – increasing their bactericidal capacity. Although, the relevance of increased 
phagocytosis to viral infections is unclear. Thus, CD4 T cells can be divided into at least two 
subsets in some ways reflecting humoral and cellular immunity; TFH and non-TFH– more 
specifically TH1 (in viral infection). There is likely to be considerable plasticity between these 
two phenotypes, but at first approximation this distinction allows us to understand the function of 
CD4 T cells with some structure.  
 The CD8 T cell response is characterized by heterogeneity that mainly arises from an 
inverse correlation between the generation of long-lived “memory” cells and “short-lived” 
effector cells18,20. This separation is rooted in both cell surface marker expression, and 
differential expression of transcription factors. It is currently thought that high levels of 
inflammatory cytokines “drive” cells to become short-lived effectors characterized by KLRG1 
expression and lack of IL-7Ra (CD127) expression. Memory cells exhibit higher survival 
following transfer and have increased proliferative capacity compared to short lived effectors. 
These functiosn are likely programmed by transcription factors; T-bet, Blimp-1, Zeb2, and Id2 
are characteristic of effector CD8 T cells while memory cells express higher levels of Eomes, 
TCF-1, Bcl6, and Bach2 18,20.  
 Our discussion so far has been generalized to “acute” infection in which the host clears 
the pathogen or succumbs to disease in 7-10 days. These types of infections are typically caused 




with persistent viral antigen such as HIV, Hepatitis B and C22. In addition many viruses remain 
in a latent state such as herpesviruses which are under constant immune surveillance, likely 
providing constant antigenic stimulation23. Under conditions of high antigen load, CD8 T cells 
exhibit altered ex vivo phenotypes including decreased cytokine production and cytolysis of 
targets24,25 . This phenomenon has been termed T cell “exhaustion”. This phenotype has been 
correlated with cell surface marker expression most notably PD-1, but also other inhibitory 
receptors including Tim-3, LAG-3, and 2B426. However, it must be noted that these molecules 
can be expressed in any activated T cell, and thus are not specific markers of an exhausted T 
cells. Importantly, their functional roles are highlighted in genetic inactivation of antibody-based 
blockade experiments which can in some cases “reverse” this exhausted state, and “reinvigorate” 
the T cell response27. 
 The ability to improve the immune response in the context of persistent antigen begs the 
question of exactly what beneficial role do these inhibitor receptors play in the host in natura. 
One answer comes from the partial role these molecules play in mediating tolerance and the 
prevention of autoimmunity which occurs to some extent in PD-1 deficient animals and as a side 
effect of anti-PD-1 based therapies in the clinic16,28. However, an additional answer may lie in 
the ability of T cells to cause damage to the host as a byproduct of their function in pathogen 
clearance. This phenomenon is known as immunopathology, and exists on a typical spectrum of 
altered host physiology caused by immune activation29. The relevance of these inhibitory 
receptors is they effectively “tune down” the immune response such that lethal or detrimental 
tissue damage is averted. A salient example of this concept is lethal disease following infection 
PD-1 deficient mice with certain strains of the noncytopathic virus LCMV which does not occur 




“exhaustion” can be considered a protective mechanism for the host, but viewed from another 
lens, a virulence strategy by the pathogen to persist. These issues will be tacked in the following 
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The adaptor molecule CD2AP in CD4 T cells modulates differentiation of follicular helper 
T cells during chronic LCMV infection 
 
The contents of this chapter have been previously published in Plos Pathogens. 
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CD4 T cell-mediated help to CD8 T cells and B cells is a critical arm of the adaptive 
immune system required for control of pathogen infection. CD4 T cells express cytokines and 
co-stimulatory molecules that support a sustained CD8 T cell response and also enhance 
generation of protective antibody by germinal center B cells. However, the molecular 
components that modulate CD4 T cell functions in response to viral infection or vaccine is 
incompletely understood. Here we demonstrate that inactivation of the signaling adaptor CD2AP 
promotes CD4 T cell differentiation towards the follicular helper lineage, leading to enhanced 
control of viral infection by augmented germinal center response in chronic lymphocytic 
choriomeningitis virus (LCMV) infection. The enhanced follicular helper differentiation is 
associated with extended duration of TCR signaling and enhanced cytokine production of 
CD2AP-deficient CD4 T cells specifically under TH1 conditions, while neither prolonged TCR 
signaling nor enhanced follicular helper differentiation was observed under conditions that 
induce other helper effector subsets. Despite the structural similarity between CD2AP and the 
closely related adaptor protein CIN85, we observed defective antibody-mediated control of 
chronic LCMV infection in mice lacking CIN85 in T cells, suggesting non-overlapping and 
potentially antagonistic roles for CD2AP and CIN85. These results suggest that tuning of TCR 






CD4 T lymphocytes are critical mediators of the adaptive immune response to infection 1. 
Upon encountering cognate antigen as peptide-MHC (pMHC) complexes on antigen presenting 
cells in the lymphoid organs, they initiate clonal expansion and undergo differentiation into 
effector cells, depending on the cytokine milieu initially established by innate immune cells 2. In 
response to viral infection, differentiation of activated CD4 T cells is directed towards an IFN-γ-
producing subset, refer to as TH1, that also produces IL-2 and TNF-α and enhances cellular 
immune responses by CD8 T cells and macrophages. Activated CD4 T cells also differentiate into 
the follicular helper (TFH) cells that migrate to germinal centers (GCs) 3. During viral infection, 
TFH cells provide help signals to B cells for antibody affinity maturation through their expression 
of co-stimulatory ligands and cytokines, such as CD40L and IL-21, and direct Ig class switching 
to the antiviral IgG2a/c subclass by secreting IFN-γ 4. Thus, understanding the molecular 
mechanisms governing CD4 T cell responses through either TCR-dependent or cytokine-
dependent signals can yield insight into host protection against viral infection or protective 
antibodies induced by vaccines. 
Following ligation of the TCR by cognate pMHC complexes, re-organization of membrane 
proteins and post-translational modification of signaling components, ultimately result in 
activation of genes necessary for their proliferation and effector differentiation 5. At the TCR-
juxta-membrane regions, the TCR itself and its proximal kinases are densely packed and 
surrounded by adhesion molecules, such as LFA1 integrin, which together comprise the 
immunological synapse (IS) and facilitate quality control of TCR signals 6. A number of previous 
studies have demonstrated that repeated cycles of this brief activation of TCR fine-tune the quality 




mechanisms are common across different effector subsets, or whether the altered regulation may 
have impact on CD4 T cell immune responses in vivo. 
The closely related proteins, CD2AP and CIN85, are scaffolding molecules that possess 
three tandem SH3 domains, a proline rich domain, and a C-terminal coiled-coil domain that 
mediates their hetero/homodimerization 8. CD2AP was originally identified via a yeast two-hybrid 
screen as an interacting partner of the adhesion molecule CD2 and a dominant negative form 
expressed in Jurkat T cells prevented formation of the immunological synapse 9. However, in naive 
T cells from AND TCR transgenic mice lacking CD2AP, formation of the immunological synapse 
was intact, suggesting that CD2AP functions independently of CD2 in primary T cells 10. 
Interestingly, following stimulation with pMHC, activation of proximal kinases and degradation 
of TCR are delayed, leading to prolonged TCR activation and enhanced cytokine production in 
vitro 10. However, the role of CD2AP in tuning of TCR signaling in T cell immune responses or 
the impact of altered TCR signaling quality in vivo caused by Cd2ap deficiency has not been 
defined due to a fatal kidney disease that develops around 3 weeks of age in Cd2ap–/– mice 11. 
Here, we generated T cell-specific Cd2ap–/– deficient mice and show that CD2AP 
deficiency enhances control of chronic viral infection by augmenting antiviral TFH and GC 
responses. In contrast, TFH and GC responses were minimally altered when the mice were 
immunized with sheep red blood cells, which are prone to elicit type 2 responses 12. TCR signaling 
in Cd2ap–/– CD4 T cells was prolonged specifically under TH1 conditions in vitro, resulting in 
increased production of IFN-γ, while CD2AP was dispensable for temporal tuning of TCR signals 
in TH2 or TH17 cells. These results demonstrate that CD2AP-dependent tuning of TCR signaling 
in CD4 T cells is TH subset-specific and that CD2AP may be an effective target to accelerate the 




2.3 RESULTS  
 
TFH differentiation is enhanced in CD2AP-deficient mice late in acute viral infection 
To conduct analyses of function of CD2AP in T cells in vivo, we generated the Cd2ap-flox 
allele, in which expression of cre recombinase results in deletion of exon 2 (Fig 1A). This allele 
was bred to Cd4-cre to inactivate Cd2ap in T cells. Numbers of mature CD4 and CD8 single 
positive thymocytes and CD4 and CD8 T cells in the spleen were comparable between Cd4-cre+ 
Cd2apF/F and control Cd2apF/F mice (Fig 1, B and C). 
To define the role of CD2AP in T cells in vivo, we infected Cd4-cre+ Cd2apF/F and control 
Cd2apF/F littermate control mice with the Armstrong strain of lymphocytic choriomeningitis virus 
(LCMV), which elicits acute antiviral responses and is cleared by CD8 T cells. At the peak of the 
T cell response on day 8 after infection, no difference was seen in numbers of total CD8 T cells, 
KLRG1+ short-lived effector CD8 T cells or that of LCMV glycoprotein (gp)-specific CD8 T cells 
between Cd4-cre+ Cd2apF/F and Cd2apF/F mice (Fig 2A, 2B, and 2D), suggesting that CD2AP is 
not required for normal CD8 T cell responses to acute LCMV infection. Comparable numbers of 
LCMV-gp-specific CD4 T cells also were detected in both genotypes eight days after infection 
(Fig 2C and 2D), suggesting that CD2AP is dispensable for priming and initial expansion of 
LCMV-specific CD4 T cells. Both Cd2ap–/– and control LCMV-specific CD4 T cells differentiated 
into Ly6C+ TH1 effector cells or TFH cells as defined by CXCR5 and PD-1 expression on day 8 
after infection (Fig 2E and 2F). Accordingly, we did not observe a difference in either frequency 
or absolute number of Fas+ GL7+ GC B cells at this time point (Fig 2E and 2F). At a later time-
point (day 22), however, the frequency and absolute number of total and LCMV-specific CXCR5+ 




mice (Fig 2G and 2H). These results indicate that Cd2ap-deficiency enhances CD4 T cell 
differentiation into the TFH subset following initial bifurcation between TH1 effector and TFH fates 
early in infection, and augments GC B cell responses. 
To determine whether TFH differentiation of Cd2ap–/– CD4 T cells is also enhanced by 
immunization that induces other types of CD4 T cell responses, we analyzed the GC response after 
immunization of Cd4-cre+ Cd2apF/F and Cd2apF/F mice with SRBCs, which predominantly induces 
development of IL-4 producing CD4 T cells 13,14. While in the absence of CD2AP, a statistically 
insignificant trend in increased TFH and GC responses was seen at day 12 following immunization, 
a relatively late time point when antigen levels are declining 15 (Fig 3A-3H), numbers of TFH and 
GC B cells were comparable between Cd4-cre+ Cd2apF/F and Cd2apF/F mice both at a relatively 
early time point, day 6, and a later time point day 22 (Fig 4, A to D). In addition, we found no 
significant differences in TFH and GC B cell numbers between Cd4-cre+ Cd2apF/F and Cd2apF/F 
mice following immunization with NP-CGG precipitated in aluminum salts (Fig 4, E and F), 
which also induces a preferential TH2 biased CD4 T cell response 16. These results suggested that 
CD2AP suppresses CD4 T cell differentiation towards the follicular helper subset dependent on 
the context in which the response is induced. 
 
Enhanced control of chronic LCMV infection in T cell-specific Cd2ap-deficient mice 
While we observed enhanced TFH differentiation in Cd2ap-deficient mice to LCMV-
Armstrong, CD8 CTLs rather than LCMV-specific antibodies are required for control of acute 
LCMV infection 17. To determine whether enhanced TFH differentiation seen in CD2AP deficiency 




c13) model of chronic viral infection since TFH-dependent high affinity antibody responses in the 
GCs and class-switch recombination to IgG2a/2c subclasses are required for control of the 
infection 18-20. After infection, LCMV replicated and established viremia to a similar extent in Cd4-
cre+ Cd2apF/F and control cre– Cd2apF/F mice on day 8 (Fig 5A). In control cre– Cd2apF/F mice, 
viral abundance, as determined by the quantities of the LCMV gp transcript in the plasma of mice, 
started to gradually decline around day 30 (Fig 3A), coinciding with expansion of TFH and GC B 
cells in response to a surge of IL-6 production by follicular dendritic cells 18. The decline in LCMV 
abundance was significantly accelerated in Cd4-cre+ Cd2apF/F mice, with the viral titers below the 
limit of detection in some Cd4-cre+ Cd2apF/F mice by day 45 (Fig 5A and 6A). Consistent with 
the accelerated clearance of LCMV, the frequencies and numbers of total and LCMV gp-specific 
TFH cells in the spleen 22 days after infection were significantly increased (Fig 5, B and D; 6 B 
and C), although total numbers of LCMV-specific CD4 T cells were not changed in Cd4-cre+ 
Cd2apF/F mice compared to control mice (Fig 5D). Accordingly, frequencies and numbers of GC 
B cells were significantly increased in Cd4-cre+ Cd2apF/F mice compared to control mice (Fig 5C 
and 5E; Fig 6D). It has been demonstrated that T follicular regulatory (TFR) cells can suppress the 
GC response 21; thus we analyzed the frequency of Foxp3+ cells within the TFH compartment, 
however, we did not find differences between genotypes indicating TFR differentiation was 
unimpaired (Fig 6, E and F). Moreover, plasma from Cd4-cre+ Cd2apF/F mice exhibited elevated 
neutralizing activity against LCMV in vitro, while titers of total anti-LCMV antibodies with 
dominant IgG2c and sub-dominant IgG1 subclasses were comparable between Cd4-cre+ Cd2apF/F 
and control Cd2apF/F mice (Fig 5F; 6G). As a measure of GC output we also analyzed the number 
of memory B cells and plasma cells in the bone marrow at 60 days following LCMV-c13 infection 




suggesting enhanced acquisition of mutations rather than total output contributed to the phenotype 
(Fig 7). Given the importance of CD4 T cell help in promoting long-lived polyfunctional CD8 T 
cells we also analyzed the CD8 T cell response at day 22 22,23. Importantly, we did not detect 
differences in overall CD8 T cell numbers or LCMV-specific H-2Db(gp33-41) tetramer binding T 
cells in Cd4-cre+ Cd2apF/F mice compared to control mice (Fig 8A and B). In addition, we did not 
observe differences in the polyfunctionality of LCMV-specific CD8 T cells as determined by IFN-
γ and TNF-α production (Fig 8C). These results indicate that while inactivation of CD2AP only 
minimally affects the CD8 T cell response, it enhances TFH differentiation and generation 
neutralizing antiviral antibodies by augmenting B cell help. 
 
CD2AP deficiency promotes TFH differentiation in a cell-intrinsic manner 
To determine whether the increased TFH differentiation in Cd4-cre+ Cd2apF/F mice was cell-
intrinsic, we generated BM chimeras by transferring a mixture of BM cells from Cd4-cre+ Cd2apF/F 
or cre–Cd2apF/F mice (CD45.2) and CD45.1 WT mice into lethally irradiated CD45.1 WT mice. 
Following reconstitution of donor-derived hematopoiesis, the recipient mice were infected with 
LCMV-c13 and contribution of Cd2ap-deficient and -sufficient cells to the TFH compartment was 
examined 22 days after infection (Fig 9A). While the percentages of CD45.2 cells in the B cell 
and CD44lo PD-1– naive CD4 T cell compartments were equivalent between chimeras 
reconstituted with Cd4-cre+ Cd2apF/F or cre– Cd2apF/F BM cells, the contribution of CD45.2 cells 
to the CXCR5+ PD-1+ TFH pool was significantly greater in chimeras receiving Cd4-cre+ Cd2apF/F 
compared to control chimeras receiving cre– Cd2apF/F BM cells (Fig 9B). In addition to the 




expressed elevated levels of genes that are associated with TFH functions, including Il21, Il21r and 
Il17ra, and also those associating with active cell cycling (Fig 9C) 24. We confirmed these results 
by analysis of frequencies of Ki67+ cells within TFH cells and found them to be increased in KO 
cells compared to WT (Fig 6H). In contrast these changes, we did not observe changes in 
expression of TFH associated molecules such as ICOS and OX-40, suggesting these costimulatory 
pathways might not contribute to the observed phenotype (Fig 6I). These results suggest that 
Cd2ap-deficient CD4 T cells are maintaining highly activated states, potentially through enhanced 
TCR-dependent signaling, and establish a stable TFH program potentially by the IL-21-IL-21R 
feed-forward loop and thus better support GC B cell responses against viral infection. 
 
CD2AP-deficiency causes sustained TCR activation specifically in TH1 cells 
Our data demonstrated that TFH differentiation was enhanced by Cd2ap-deficiency 
specifically in viral infection, but not in immunization with SRBCs or NP-CGG in alum. These 
results suggest that CD2AP regulates TCR signaling in a TH-subset-specific manner. To dissect 
the subset-specific role of CD2AP in CD4 T cells, we activated naive CD4 T cells from Cd4-cre+ 
Cd2apF/F and control Cd2apF/F cells under polarizing conditions that promote generation of TH1 or 
TH2 cells and compared their responses to antigen receptor stimulation (Fig 10A). While 
production of IL-4 under TH2 conditions was comparable between Cd2ap-deficient and -sufficient 
CD4 T cells, the production of IFN-γ was increased by 3-fold in Cd2ap-deficient TH1 cells 
compared to control cells (Fig 10B). Consistently, activation of the MAPK pathway was prolonged 
specifically in Cd2ap-deficient TH1 compared to control TH1 cells, whereas we did not observe 




deficient mice showed that Cd2ap–/– TCR-transgenic naive T cells are defective in TCR 
downregulation 10. In polarized TH1 cells, downmodulation of surface TCRs was significantly 
impaired in the absence of CD2AP, while the difference was not observed under TH0, TH2 or TH17 
conditions between Cd2ap-deficient and -sufficient CD4 T cells (Fig 10D). Furthermore, when 
Cd2ap-deficient and control TH1 cells were re-stimulated with plate-bound anti-CD3 and anti-
CD28 antibodies or with PMA and Ionomycin for 4 hours, similar frequencies of cells expressed 
IFN-γ and TNF-α (Fig. 10,E and F). However, when they were stimulated with plate-bound anti-
CD3 and anti-CD28 antibodies for 24 hours, the frequencies of cells that expressed IFN-γ or TNF-
α during the last 2 hours of the stimulation were significantly increased in Cd2ap-deficient TH1 
cells relative to WT TH1 cells presumably due to prolonged retention of TCR on the cell surface, 
which was crosslinked by the plate-bound antibodies (Fig. 10, E and F). These results indicate 
that CD2AP deficiency prolongs TCR signaling specifically in CD4 T cells under TH1 conditions. 
 
CIN85 plays a non-redundant role in T cell-dependent control of LCMV infection 
CIN85 and CD2AP are closely related and may have redundant functions 8,12 . To test 
this, we also generated mice in which T cells are deficient for CIN85 by breeding a Cin85-flox 
allele to both Cd4-cre 25. Cd4-cre+ Cin85F/F mice exhibited no differences in CD4 T and CD8 T 
cell response to acute LCMV infection (Fig 11). However, in contrast to Cd4-cre– Cd2apF/F 
mice, Cd4-cre+ Cin85F/F mice were unable to control chronic LCMV infection with significantly 
higher viral burden in the peripheral blood at days 45 and 60 after infection compared to cre– 
littermate controls (Fig 13A). In addition, while all WT mice had cleared virus from the plasma 




clearance phenotype was more pronounced when we infected Vav1-icre+ Cin85F/F mice, in which 
all hematopoietic cells, including B cells, were deficient for Cin85 (Fig 12A), suggesting CIN85 
plays additional roles in other hematopoietic cells in the context of LCMV-c13 infection, 
potentially through B cells as previously reported 25. However, when we analyzed mice at day 30 
following infection we did not find any significant differences in either frequency or absolute 
number of CD8 T cell, TFH, or GC response (Fig 12, B to D). Consistently, when we analyzed 
Cd4-cre+ Cin85F/F mice, the frequency of Fas+ GL7+ GC B cells was only marginally, but 
insignificantly, decreased in Cd4-cre+ Cin85F/F mice compared to control Cin85F/F mice (Fig 
13C) with anti-LCMV IgG titers unchanged, suggesting no severe defects in the GC response 
(Fig 13D). However, plasma from infected Cd4-cre+ Cin85F/F mice exhibited a significantly 
reduced neutralizing activity compared to plasma from cre– littermate controls (Fig 13E). These 
results indicate that CIN85 is required for protective antibody responses in a T cell-dependent 
manner presumably through controlling TFH function and potentially the quality of help provided 
to GC B cells with respect to generation of high-affinity neutralizing antibodies required for 
clearance of chronic LCMV 26. These results suggest that although CD2AP and CIN85 share 







This study demonstrated that deletion of CD2AP in T cells results in skewing of CD4 T 
cell differentiation towards TFH cells in response to viral infection, leading to enhanced control of 
LCMV that requires GC-derived high affinity antibody responses 18,20,27. TFH differentiation was 
correlated with sustained TCR signaling under TH1 conditions, while TCR signaling in vitro 
under non-TH1 conditions was not altered. Thus, our work revealed a specific role of CD2AP in 
subset-specific CD4 T cell responses. 
Sustained TCR stimulation during chronic LCMV infection or in the cancer 
microenvironment causes deregulation of CD8 T cells, a phenomenon known as exhaustion 1,28. 
Frequent interactions with cognate pMHC-I result in the persistent upregulation of several 
inhibitory receptors which act to dampen T cell proliferation and effector functions, a hallmark 
of the “exhausted state” 2,28. However, the impact of sustained TCR stimulation on the function 
of CD4 T cells has been less clearly understood. In chronic LCMV infection, CD4 T cells exhibit 
less IL-2 production and increased IL-10 production, a phenomenon that is similar in nature to 
CD8 T cell “exhaustion” 3,29-31. However, these CD4 T cells with the altered activation state 
acquire the capability of producing IL-21, a key cytokine that enhances the GC response and also 
supports the CD8 T cell response; both are required for control of the viral infection 4,30-32. Thus, 
although sustained TCR signaling compromises CD8 T cell functions, CD4 T cells are able to 
tolerate sustained signaling through TCR to mediate pathogen control. 
Several recent studies indicate that during chronic LCMV infection, CD4 T cells exhibit a 
relatively unique propensity to acquire TFH features, a process that is dependent on continuous 




different compared to acute LCMV infection 34. Interestingly, in late phases >day 20 of LCMV-
c13 infection B cells do not appear to be absolutely required for the development of CXCR5+ 
cells, suggesting other types of antigen presenting cells could contribute to the sustained TFH 
response as this does not occur in MHCII KO 33. Preferential TFH accumulation has also been 
shown to be dependent on type-I Interferon 6,35 which has not been explicitly observed in acute 
contexts, via a cell-extrinsic mechanism, suggesting other soluble or cell-associated factors could 
have a more direct influence 35. These results illustrate the complexity in direction of the CD4 T 
cell response, and illustrate the variety of mechanisms than influence the humoral response in 
response to the nature of the insulting pathogen. However, in several contexts it appears that 
modulation of TCR affinity and or signal duration impacts the differentiation of TFH cells, 
supporting a more broadly applicable role for the TCR. 
Our study with CD2AP-deficient T cells confirm and extend previous studies that suggest 
that sustained TCR signaling promotes TFH differentiation 36,37. Specifically, it was shown 
following infection by Listeria monocytogenes that TCR:pMHCII dwell time correlated well 
with GC-TFH differentiation 36. In addition, in antigen-specific cells elicited by immunization 
with pigeon cytochrome c, TFH phenotype cells tended to have higher affinity for tetramer 
compared to non-TFH cells, and transfer of TCR transgenic cells with higher affinity for pMHCII 
revealed a preference for TFH differentiation 37. One potential explanation is that TFH and TH1 
cells may share a transitional stage, at which sustained TCR signaling may restrict T-bet 
upregulation to direct the activated CD4 T cells into the TFH subset, which favors low-T-bet 38, 
while TFH differentiation during a type-2 immune response may require a distinct mechanism. 
This may explain why TFH differentiation is enhanced when CD4 T cells receive sustained TCR 




IL-21 expression by Cd2ap-deficient CD4 T cells did not noticeably alter the CD8 T cell 
response, which is also dependent on CD4 T cell help. These results potentially indicate that the 
nature of CD4 T cell help to B cells and CD8 T cells may be independent. 
While downregulation of the TCR and subsequent termination of TCR downstream 
signaling is broadly shared by T cells, our results indicate that CD2AP-dependent regulation of 
TCR signaling duration is TH1-specific in vitro, which correlates with enhanced TFH 
differentiation in LCMV infection. However, it still remains unclear whether the in vivo 
functions of CD2AP are completely explained by TCR signaling via the immunological synapse, 
interactions with CD2, or potentially via signaling via other cytokines such as IL-21 or Type I 
interferon and is an area of further investigation. Notably, a recent study reported TH2-specific 
regulation of the duration of TCR signaling by the Rab-GTPase Dennd1b 39. Dennd1b-deficiency 
in CD4 T cells results in sustained TCR signaling and increased cytokine production specifically 
under TH2 conditions. Furthermore, a DENND1B SNP in human, causing reduced expression of 
its protein, is associated with asthma. These two studies, contrasting lineage-specific requirement 
for CD2AP and Dennd1b in controlling TCR signaling in TH1 and TH2 cells, respectively, imply 
that the control of TCR signaling may be uniquely regulated by different CD4 effector subsets. 
Despite strong correlations between sustained duration of TCR signaling in vitro and enhanced T 
cell polarization in vivo in Cd2ap-deficient mice and Debbd1b-deficient mice, however, there 
may be additional mechanisms, such as cell-cell contact or signaling through CD2, by which T 
cell polarization are enhanced in these genetically modified mice.  
Our study highlights CD2AP as a potential target for immunotherapy to enhance B cell 
immune responses. Given the importance of high-affinity neutralizing antibodies in the clearance 




therapeutic target. The development of small molecules that inhibit the function of CD2AP in the 
context of viral infection or in the context of vaccines, could enhance the antibody response. TFH 
responses, however, have also been associated with the development of autoantibodies and 
autoimmunity. 
Collectively, our results demonstrate that the quality of TCR signaling is regulated by 
distinct mechanisms in CD4 effector T cells, and regulates differentiation of antigen-specific 





2.5 MATERIALS AND METHODS 
Ethics Statement 
Overall care and use of the animals was consistent with The guide for the Care and Use 
of Laboratory Animals from the National Research Council and the USDA Animal Care 
Resource Guide and were performed according to a protocol approved by Washington 
University’s Animal Studies Committee under a protocol number of 20150187, which was 
approved on 10/26/2015 and expires 10/9/2018. Euthanasia procedures are consistent with the 
“AVMA guidelines for the Euthanasia of Animals 2013 edition.” 
 
Mice 
C57BL/6N and B6-CD45.1 mice were purchased from Charles River Laboratory. Cd4-
cre mice   in the C57BL/6 background were purchased from the Jackson Laboratory. A Cin85-
floxed allele was described previously 25. To generate a Cd2ap-flox allele, a genomic fragment 
containing Cd2ap exon2 was flanked with two loxP sites and subcloned into a vector containing 
a loxP-flanked neomycin resistant gene, a diphtheria toxin A (DTA) gene, and a 6.0-kb 5’ and a 
2.1-kb 3’ homology arm. The targeting vector was electroporated into C57BL/6-derived Bruce4 
embryonic stem (ES) cells. After the selection with G418 (Thermofisher), correctly targeted 
clones were identified by PCR. The neomycin resistant gene was removed by a transient 
transfection of a cre expression vector. The targeted ES clones were injected into blastocysts of 
BALB/c mice. The chimeric mice were crossed with C57BL/6 mice to obtain germline 




reconstituted with donor BM cells for at least 8 weeks before experiments. All mice were housed 
in a specific pathogen-free facility at Washington University in St. Louis, and were analyzed at 8 
to 10 weeks of age, unless stated otherwise. Both sexes were included without randomization or 
blinding. 
 
LCMV Infection and Immunization 
Mice were infected with 2 x 105 plaque-forming units (PFU) of LCMV-Armstrong strain 
via the intraperitoneal route or 2 x 106 (PFU) of LCMV-c13 by intravenous injection. For the 
quantification of plasma viral load, RNA was extracted from 10 μL of plasma using Trizol (Life 
Technologies). Before RNA extraction a spike-in of RNA extracted from 293T cells (American 
Type Culture Collection, ATCC) expressing gfp mRNA was added to the plasma samples. The 
amounts of the LCMV GP transcript relative to that of ‘‘spiked- in’’ gfp RNA were determined 
by real-time qRT-PCR as previously described 20,40 .For plasma viral titers, plasma was frozen at 
-80˚C before performing plaque assay on Vero cells as previously described. Briefly, 7.5 x 105 
Vero cells (ATCC) were plated per well of a 6-well plate 24 hour prior to incubation with serial 
10-fold dilutions of plasma in 200 μL of MEM/1%FBS (Thermofisher) for 1 hour at 37˚C. 
Following the incubation Vero cells were overlaid with 0.5% Agarose (Thermofisher) solution in 
complete MEM and incubated for 5-6 days. Plaques were visualized following fixation in 1% 
PFA (Electron Microscopy Sciences) and staining with 0.1% crystal violet (Sigma). 
In vitro neutralization assay was performed according to a published protocol with some 
modifications 26. Heat-inactivated (1 hr at 55˚C) plasma were serially diluted with media and 




(FFU) of LCMV clone 13 at 37˚C for 90 min. 4 x 104 MC57G cells (ATCC) were added to the 
virus mixture and once the cells had adhered to the plate ~4 hours, were overlaid with a 1% 
methylcellulose solution in completed DMEM. 40 hours following infection, overlay was 
removed, and cells were fixed with 4% PFA for 1 hour at RT. Cells were permeabilized with 
0.5% Triton X-100 in PBS and blocked with 10% FBS in PBS. Cells were stained with 1ug/mL 
of anti-LCMV NP (VL-4; BioXCell) for 1 hour at RT followed by anti-rat IgG HRP. Foci were 
developed using KPL TrueBlue Substrate. 
Mice were immunized with 8-10 x 108 SRBC (Lampire) in 200 μL via the intraperitoneal 
route or with 100μg of NP-CGG (Biosearch Technologies) precipitated Potassium Aluminum 
Sulfate (Sigma).  
 
Flow cytometry and Cell Sorting 
Single-cell suspensions were prepared by manual disruption of spleens with frosted glass 
slides. Absolute cell counts were determined using Vi-Cell (Becton-Dickson). The following 
monoclonal antibodies were used: anti-CD4 (GK1.5; Biolegend), anti-CD8a (53-6.7; Biolegend), 
anti-CD25 (PC61; Biolegend), anti-CD44 (IM7; Biolegend), anti-CD45.2 (104; Biolegend), anti-
CD45R (B220) (RA3-6B2; Biolegend), anti-CD62L (MEL-14; Biolegend), anti-CD95 (Fas) 
(Jo2; BD Biosciences), anti-KLRG1 (2F1/KLRG1; Biolegend), anti-IFN-γ (XMG1.2; 
eBioscience), anti-TCRb (H57-597; eBioscience), anti-PD-1 (29F.1A12; Biolgend), anti-CXCR5 
(2G8; BD Biosciences) or anti-CXCR5 (L138D7; Biolegend), anti-Ly6C (HK1.4; Biolgend), and 




For sorting of naive CD8 T cells, splenocyte samples were initially depleted of B220+ 
cells through the use of magnetic beads (Thermofisher). CD4 T cells were negatively selected 
using the Dynabeads FlowComp Mouse CD4 Kit (Thermofisher) and then were stained with 
monoclonal antibodies to purify CD62L+ CD44− CD25− cells on a FACSAria II or FACSAriaIII 
(BD Biosciences). For phenotypic analysis, cells were stained with monoclonal antibodies, 
phycoerythrin (PE)-conjugated H-2Db-gp(33-41) (MBL International) for 1 hour at RT or PE-I-
Ab(gp66-77) (obtained from NIH Tetramer Core) for 90 minutes at 37˚C. Dead cells were 
excluded by staining with DAPI (4,6-diamidino-2-phenylindole; Sigma). Data were analyzed 
with FlowJo software (TreeStar). 
 
In Vitro T cell Culture 
Sort purified naive (CD62L+ CD44lo CD25–) CD4 or CD8 T cells were cultured in RPMI 
1640 medium supplemented with 10% FBS (Thermofisher) and Gluta-MAX in the presence of 
plate-bound anti-CD3 (145-2C11; Biolegend) and soluble anti-CD28 (37.51; Bio X Cell) at 
concentrations of 0.1 μg/ml and 0.5 μg/ml, respectively, unless specified otherwise, in multiwell 
tissue culture plates coated with rabbit antibody to hamster IgG (0855395; MP Biomedicals). For 
TH1 polarization 10 ng/mL of IL-12 (R&D Systems) and 10 μg/mL of anti-IL-4 (11B11) were 
added to culture media. For TH2 polarization 10 ng/mL IL-4 (eBioscience), 10 μg/mL anti-IL-12 
(BioXCell), and 10 μg/mL anti-IFN-γ (Biolegend) were added to culture media. Following 3 
days of anti-CD3 and anti-CD28 stimulation cells were removed from stimulation and rested for 
3 days in conditioned medium at concentration of 0.5-1 x 106 cells/mL. For CD8 T cell cultures, 




Day 6 CD4 T cells were harvested, washed in fresh media, and restimulated using 50 
ng/mL PMA (Sigma) and 1 μM Ionomycin (Sigma) or plate-bound anti-CD3 (Biolegend) and 
soluble anti-CD28 (BioXcell) as described above for the indicated times. For intracellular 
cytokine analysis, Brefeldin A (Biolegend) was added to the cultures 2 hours before harvest. 
Supernatant was collected 24 hours post-stimulation. 
 
ELISA 
ELISA for cytokines was performed on Nunc Maxisorp plates using ELISA MAX IFN-γ 
and IL-4 kits (Biolegend) and developed using TMB substrate (Dako). OD450 values were read 
on a spectrophotometer. Standard curves for these ELISAs were generated with purified 
cytokines. 
Anti-LCMV ELISA was performed as previously described 41. Nunc Polysorp plates 
were coated with 10ug/mL sonicated cell lysate from LCMV-infected BHK-21 cells (gift from 
Marco Colonna, Washington University) as capture antigen or uninfected BHK-21 cell lysate 
overnight followed by UV irradiation (300 mJ in Stratalinker 1800; Stratagene). Plasma antibody 
was detected with biotinylated anti-mouse IgG1 antibody (BD) and anti-mouse IgG2c antibody 
(1077-08; Southern Biotech). Endpoint titers were calculated by a sigmoidal-dose response curve 
using a Graphpad Prism 7 software. 
 




Cells were subject to LIVE/DEAD Aqua staining (Thermofisher) for 30 minutes at 4˚C 
before being fixed with 4% PFA for 10 minutes at RT. Cells were washed twice with 0.03% 
saponin (Sigma) in 2% FBS/PBS before being stained with the indicated antibodies in 0.3% 
Saponin in 2% FBS/PBS for 20 min at 4˚C. 
 
T cell stimulation and western blotting 
In vitro polarized T cells were rested for 1 hour in cytokine-free RPMI medium before 
being stained with 5 μg/mL anti-CD3 and 5 μg/mL anti-CD28 on ice for 20 minutes. TCR was 
then crosslinked by addition of 20 μg/mL of anti-Armenian Hamster IgG to the cells on ice. Cells 
were stimulated in 5 ml polystyrene tubes for the indicated times in a water bath at 37˚C. Cells 
were lysed in NP-40 Lysis Buffer (1% NP-40, 50 mM Tris-HCl (pH7.5), 150 mM NaCl, 2 mM 
EDTA, phosphatase inhibitors) and cleared via centrifugation at 14,000 rpm for 10 minutes, then 
denatured in SDS sample buffer. 
Lysates from equal numbers of cells were separated by 8% or 10% SDS PAGE and 
transferred to nitrocellulose membranes (Bio-Rad), which were incubated with primary 
antibodies (identified below), followed by detection with horseradish peroxidase–conjugated 
species-specific antibody to immunoglobulin light chain (115-035-174 or 211-032-171; Jackson 
ImmunoResearch) and a Luminata HRP substrate (Millipore). The following antibodies were 







Total RNA was extracted from ~300,000 sorted cells using manufacturer’s instructions 
using the RNA XS Kit (Macherey Nagel). cDNA synthesis and amplification were performed 
with a Pico Input RNA Kit, according to the manufacturer's instructions (Clontech). Libraries 
were sequenced on a HiSeq3000 (Illumina) in single-read mode, with a read length of 50 
nucleotides producing ~25 million reads per sample. Sequence tags were mapped onto the 
NCBI37 mm9 with TopHat 42. followed by transcript assembly and RPKM estimation using 
Cufflinks 43-45 on the Galaxy platform (https://usegalaxy.org/). The raw data has been deposited 
at NCBI GEO with an accession number GSE112778. 
 
Statistical Analyses 
Statistical analyses were performed with a two-tailed unpaired Student’s t-test or a Mann-






We thank the NIH tetramer core facility at Emory for LCMV-gp66-77 tetramer, Chris 






2.7 AUTHOR CONTRIBUTIONS 
 Conceptualization: Andrey S. Shaw, Takeshi Egawa. 
 Data curation: Saravanan Raju, Takeshi Egawa. 
 Formal analysis: Saravanan Raju. 
 Funding acquisition: Andrey S. Shaw, Takeshi Egawa. 
 Investigation: Saravanan Raju, Takeshi Egawa. 
 Project administration: Takeshi Egawa. 
 Resources: Kohei Kometani, Tomohiro Kurosaki, Takeshi Egawa. 
 Supervision: Takeshi Egawa. 
 Writing ± original draft: Saravanan Raju, Takeshi Egawa. 
 Writing ± review & editing: Saravanan Raju, Kohei Kometani, Tomohiro Kurosaki, Andrey S. 






1. Swain, S. L., McKinstry, K. K. & Strutt, T. M. Expanding roles for CD4+ T cells in 
immunity to viruses. Nature Reviews Immunology 12, 136–148 (2012). 
2. Zhu, J., Yamane, H. & Paul, W. E. Differentiation of Effector CD4 T Cell Populations. 
Annu. Rev. Immunol. 28, 445–489 (2010). 
3. Vinuesa, C. G., Linterman, M. A., Yu, D. & MacLennan, I. C. M. Follicular Helper T 
Cells. Annu. Rev. Immunol. 34, 335–368 (2016). 
4. Vinuesa, C. G., Linterman, M. A., Goodnow, C. C. & Randall, K. L. T cells and follicular 
dendritic cells in germinal center B-cell formation and selection. Immunol. Rev. 237, 72–
89 (2010). 
5. Smith-Garvin, J. E., Koretzky, G. A. & Jordan, M. S. T Cell Activation. Annu. Rev. 
Immunol. 27, 591–619 (2009). 
6. Bromley, S. K. et al. The immunological synapse. Annu. Rev. Immunol. 19, 375–396 
(2001). 
7. Čemerski, S. et al. The Balance between T Cell Receptor Signaling and Degradation at the 
Center of the Immunological Synapse Is Determined by Antigen Quality. Immunity 29, 
414–422 (2008). 
8. Dikic, I. CIN85/CMS family of adaptor molecules. FEBS Lett. 529, 110–115 (2002). 
9. Dustin, M. L. et al. A novel adaptor protein orchestrates receptor patterning and 




10. Lee, K.-H. et al. The immunological synapse balances T cell receptor signaling and 
degradation. Science 302, 1218–1222 (2003). 
11. Shih, N. Y. et al. Congenital nephrotic syndrome in mice lacking CD2-associated protein. 
Science 286, 312–315 (1999). 
12. Ismail, N., Basten, A., Briscoe, H. & Bretscher, P. A. Increasing the foreignness of an 
antigen, by coupling a second and foreign antigen to it, increases the T helper type 2 
component of the immune response to the first antigen. Immunology 115, 34–41 (2005). 
13. Stamm, C. et al. Dose-Dependent Induction of Murine Th1/Th2 Responses to Sheep Red 
Blood Cells Occurs in Two Steps: Antigen Presentation during Second Encounter Is 
Decisive. PLoS ONE 8, e67746–10 (2013). 
14. Bretscher, P. A. On the Mechanism Determining the Th1/Th2 Phenotype of an Immune 
Response, and its Pertinence to Strategies for the Prevention, and Treatment, of Certain 
Infectious Diseases. Scand J Immunol 79, 361–376 (2014). 
15. Linterman, M. A. et al. IL-21 acts directly on B cells to regulate Bcl-6 expression and 
germinal center responses. J Exp Med 207, 353–363 (2010). 
16. Grun, J. L. & Maurer, P. H. Different T helper cell subsets elicited in mice utilizing two 
different adjuvant vehicles: The role of endogenous interleukin 1 in proliferative 
responses. Cellular Immunology 121, 134–145 (1989). 
17. Homann, D. et al. Evidence for an underlying CD4 helper and CD8 T-cell defect in B-
cell-deficient mice: failure to clear persistent virus infection after adoptive immunotherapy 





18. Harker, J. A., Lewis, G. M., Mack, L. & Zuniga, E. I. Late interleukin-6 escalates T 
follicular helper cell responses and controls a chronic viral infection. Science 334, 825–
829 (2011). 
19. Barnett, B. E. et al. Cutting Edge: B Cell-Intrinsic T-bet Expression Is Required To 
Control Chronic Viral Infection. J. Immunol. 197, 1017–1022 (2016). 
20. Chou, C. et al. The Transcription Factor AP4 Mediates Resolution of Chronic Viral 
Infection through Amplification of Germinal Center B Cell Responses. Immunity 45, 570–
582 (2016). 
21. Sage, P. T. & Sharpe, A. H. T follicular regulatory cells in the regulation of B cell 
responses. Trends in Immunology 36, 410–418 (2015). 
22. Battegay, M. et al. Enhanced establishment of a virus carrier state in adult CD4+ T-cell-
deficient mice. J. Virol. 68, 4700–4704 (1994). 
23. Matloubian, M., Concepcion, R. J. & Ahmed, R. CD4+ T cells are required to sustain 
CD8+ cytotoxic T-cell responses during chronic viral infection. J. Virol. 68, 8056–8063 
(1994). 
24. Ding, Y. et al. IL-17RA Is Essential for Optimal Localization of Follicular Th Cells in the 
Germinal Center Light Zone To Promote Autoantibody-Producing B Cells. J.I. 191, 
1614–1624 (2013). 




NF-κB pathway. J Exp Med 208, 1447–1457 (2011). 
26. Seiler, P. et al. Enhanced virus clearance by early inducible lymphocytic choriomeningitis 
virus-neutralizing antibodies in immunoglobulin-transgenic mice. J. Virol. 72, 2253–2258 
(1998). 
27. Bergthaler, A. et al. Impaired Antibody Response Causes Persistence of Prototypic T 
Cell–Contained Virus. PLoS Biol 7, e1000080–11 (2009). 
28. Wherry, E. J. & Kurachi, M. Molecular and cellular insights into T cell exhaustion. Nature 
Reviews Immunology 15, 486–499 (2015). 
29. Crawford, A. et al. Molecular and Transcriptional Basis of CD4+ T Cell Dysfunction 
during Chronic Infection. Immunity 40, 289–302 (2014). 
30. Elsaesser, H., Sauer, K. & Brooks, D. G. IL-21 is required to control chronic viral 
infection. Science 324, 1569–1572 (2009). 
31. Fröhlich, A. et al. IL-21R on T cells is critical for sustained functionality and control of 
chronic viral infection. Science 324, 1576–1580 (2009). 
32. Yi, J. S., Du, M. & Zajac, A. J. A Vital Role for Interleukin-21 in the Control of a Chronic 
Viral Infection. Science 324, 1572–1576 (2009). 
33. Fahey, L. M. et al. Viral persistence redirects CD4 T cell differentiation toward T 
follicular helper cells. J Exp Med 208, 987–999 (2011). 
34. Vella, L. A., Herati, R. S. & Wherry, E. J. CD4+ T Cell Differentiation in Chronic Viral 




35. Osokine, I. et al. Type I interferon suppresses de novo virus-specific CD4 Th1 immunity 
during an established persistent viral infection. Proc. Natl. Acad. Sci. U.S.A. 111, 7409–
7414 (2014). 
36. Tubo, N. J. et al. Single Naive CD4+ T Cells from a Diverse Repertoire Produce Different 
Effector Cell Types during Infection. Cell 153, 785–796 (2013). 
37. Fazilleau, N., McHeyzer-Williams, L. J., Rosen, H. & McHeyzer-Williams, M. G. The 
function of follicular helper T cells is regulated by the strength of T cell antigen receptor 
binding. Nature Publishing Group 10, 375–384 (2009). 
38. Lazarevic, V., Glimcher, L. H. & Lord, G. M. T-bet: a bridge between innate and adaptive 
immunity. 1–13 (2013). doi:10.1038/nri3536 
39. Yang, C.-W. et al. Regulation of T Cell Receptor Signaling by DENND1B in TH2 Cells 
and Allergic Disease. Cell 1–16 (2016). doi:10.1016/j.cell.2015.11.052 
40. McCausland, M. M. & Crotty, S. Quantitative PCR technique for detecting lymphocytic 
choriomeningitis virus in vivo. Journal of Virological Methods 147, 167–176 (2008). 
41. McCausland, M. M. et al. SAP regulation of follicular helper CD4 T cell development and 
humoral immunity is independent of SLAM and Fyn kinase. J.I. 178, 817–828 (2007). 
42. Trapnell, C., Pachter, L. & Salzberg, S. L. TopHat: discovering splice junctions with 
RNA-Seq. Bioinformatics 25, 1105–1111 (2009). 
43. Roberts, A., Trapnell, C., Donaghey, J., Rinn, J. L. & Pachter, L. Improving RNA-Seq 




44. Trapnell, C. et al. Transcript assembly and quantification by RNA-Seq reveals 
unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol 
28, 511–515 (2010). 
45. Trapnell, C. et al. Differential analysis of gene regulation at transcript resolution with 






Fig 2.1. CD2AP is dispensable for T cell development.(A) Generation of a Cd2ap-flox allele 
by gene targeting. Arrows indicate primer position for PCR. LA: long homology arm, SA: short 
homology arm, Neo: neomycin resistance cassette, DTA: diphtheria toxin A. (B, C) Flow 
cytometric analysis of expression of CD4, CD8 , TCR , CD24 and CD69 in thymocytes (B) 
and splenocytes (C) from Cd4-cre+ Cd2apF/F and control cre– Cd2apF/F mice. Numbers indicates 
percentages of cells surrounded by rectangle or polygon gates. Data are representative of 3-6 







Fig 2.2. Enhanced TFH and GC B cell responses in T cell-specific Cd2ap-deficient mice in 
response to acute viral infection.(A) Flow cytometric analysis of expression of CD4, CD8 and 
CD44 and binding of H-2Db(gp33-41) tetramer in splenocytes 8 days after LCMV-Armstrong 
infection. Total CD8 T cells and LCMV-gp33-specific CD8 T cells are shown with rectangular 
gates. (B) Expression of CD8 and KLRG1 in splenocytes 8 days after LCMV-Armstrong 
infection. (C) Expression of CD44 and binding of I-Ab(gp66-77) tetramer in CD4+ splenic T 
cells 8 days after LCMV-Armstrong infection. LCMV-gp66-specific CD4 T cells are shown with 
rectangular gates. (E, G) Expression of PD-1, CXCR5 and Ly6C and binding of I-Ab (gp66-77)+ 
tetramer of CD4+ T cells and Fas and GL7 expression in B cells in the spleens of Cd4-cre+ 
Cd2apF/F and control Cd2apF/F mice 8 (E) and 22 (G) days after infection. Follicular helper CD4 
T cells and GC B cells are shown with rectangular gates. Representative plots are shown with 
percentages of gated cells. Statistical analyses from 4-6 mice in 2 independent experiments are 





Fig 2.3. Cd2ap deficiency has a minimal impact on TFH differentiation and GC B cell responses 
following immunization with SRBCs.(A, B) Flow cytometric analysis of expression of PD-1 and 
CXCR5 on pre-gated CD4+ B220– T cells (A) and GL7 and Fas expression on CD19+ B220+ B 
Cells (B) 12 days following SRBC immunization. (C-E) Numbers and frequencies of total CD4 
T cells and CXCR5+ PD-1+ TFH in the spleen of Cd4-cre+ Cd2apF/F and control Cd2apF/F mice 12 
days after immunization with SRBCs. (F-H) Numbers and frequencies of total B cells and Fas+ 
GL7+ GC B cells in the spleen of Cd4-cre+ Cd2apF/F and control Cd2apF/F mice 12 days after 
immunization with SRBCs. Data are pooled from 2 independent experiments shown as means 






Fig. 2.4 Time-course of GC B cell response following SRBC and NP-CGG Immunization in 
Cd2ap deficient mice.(A, C, E) Flow cytometric analysis of expression of PD-1 and CXCR5 on 
pre-gated CD4+ B220– T cells and GL7 and Fas expression on CD19+ B220+ B Cells at 6 days 
(A), 22 days (C) following SRBC immunization, and (E) 10 days following Alum precipitated 
NP-CGG immunization. (B, D, F) Numbers and frequencies of CXCR5+ PD-1+ TFH and Fas+ 
GL7+ GC B cells in the spleen of Cd4-cre+ Cd2apF/F and control Cd2apF/F mice at 6 days (B), 22 
days (C) immunization with SRBC and and (F) 10 days following Alum precipitated NP-CGG 
immunization. Data are representative of 2 independent experiments shown as means and 





Fig 2.5 Enhanced control of LCMV-c13 infection in Cd4-cre+ Cd2apF/F is associated with 
elevated TFH response.(A) Analysis of LCMV abundance in plasma in mice as determined by 
LCMV gp transcript levels. Horizontal bars indicate medians. The limit of detection is shown by 
a dashed line. Statistical significance was tested by Mann Whitney U-test. (B-E) Expression of 
B220, GL7, Fas, CD4, CD44, PD-1 and CXCR5 and binding of I-Ab (gp66-77) tetramer of 
splenocytes from Cd2apF/F and Cd4-cre+ Cd2apF/F mice 22 days after LCMV-c13 infection. 
Representative plots are shown with percentages of gated cells. Statistical analyses from at least 
7-10 mice per genotype in 2 independent experiments are shown with means and standard 
deviation in (D) and (E). (F) (Left) Neutralizing activity and (Right) anti-LCMV IgG2c antibody 
titers of plasma from Cd2apF/F and Cd4-cre+ Cd2apF/F mice 60 days after LCMV-c13 infection. 
Reduction in focus forming units (FFU) in the presence of 1:10 dilution of plasma compared to 
untreated control (%Neutralization) is shown with mean and standard deviation. Cd2apF/F: n=7, 






Fig 2.6. Analysis of GC Response in CD2AP deficient mice following LCMV-c13 
infection(A) Analysis of viral plaque forming units (PFU) in Cd2apF/F and Cd4-cre+ Cd2apF/F 
mice at day 45 of LCMV-c13 infection. (B) Expression of PD-1 and CXCR5 in CD4 T cells at 
day 22 of LCMV-c13 infection in Cd2apF/F and Cd4-cre+ Cd2apF/F mice (C-D) Absolute 
numbers of (C) CD4 T cells, and TFH cells (CXCR5+PD-1+) and (D) B cells at day 22 of LCMV-
c13 infection in Cd2apF/F and Cd4-cre+ Cd2apF/F mice. (E, F) Frequencies of Foxp3+ TFH cells 22 
days following LCMV-c13 infection of Cd2apF/F and Cd4-cre+ Cd2apF/F mice. (G) Anti-LCMV 
IgG1 antibody titers of plasma from Cd2apF/F and Cd4-cre+ Cd2apF/F mice 60 days after LCMV-
c13 infection. (H) Frequencies of Ki67+ TFH cells 22 days following LCMV-c13 infection of 
Cd2apF/F and Cd4-cre+ Cd2apF/F mice. (I) Expression of ICOS and OX-40 in Naive CD4 (PD-1– 
CD44lo) CD4 T cells and CXCR5+ PD-1+ TFH cells 22 days following LCMV-Armstrong 
infection in Cd2apF/F and Cd4-cre+ Cd2apF/F mice. Data are representative of 2 independent 






Fig 2.7. Analysis of GC output following LCMV-c13 infection(A-B) Expression of B220, 
IgM, IgD, GL7, AA4.1, CD138, and CD24 of splenocytes (A) and bone marrow cells (B) of 
Cd2apF/F and Cd4-cre+ Cd2apF/F 60 days after LCMV-c13 infection. (C-D) Absolute numbers of 
(C) memory B cells in the spleen of (D) plasma cells in the bone marrow of Cd2apF/F and Cd4-
cre+ Cd2apF/F 60 days after LCMV-c13 infection. Data are representative of 2 independent 






Fig. 2.8. CD8 T cell response in CD2AP deficient mice is comparable to control mice 
following LCMV-c13 infection.(A) Expression of CD8, CD4, CD44 and PD-1 and binding of 
H-2Db(gp33-41) in Cd2apF/F and Cd4-cre+ Cd2apF/F mice 22 days after LCMV-c13 infection (B) 
Absolute quantification of (A) (C) Splenocytes from Cd2apF/F and Cd4-cre+ Cd2apF/F mice 22 
days after LCMV-c13 infection were stimulated with gp33-41 peptide and the expression of 
IFN-γ and TNF-α was analyzed. Data are representative of 2 independent experiments with n=4-









Fig. 2.9 Cd2ap-deficiency enhances TFH differentiation in a cell-intrinsic manner.(A) 
Schematic of experimental strategy for the generation of mixed BM chimeras and subsequent 
analysis of anti-LCMV responses. (B) Contribution of CD45.2 Cd2apF/F or Cd4-cre+ Cd2apF/F 
cells to B cells, activated CD4 T cells and TFH cells in the mixed BM chimeras 22 days after 
LCMV-c13 infection. Representative Data from 2 independent experiments (n=4 of each 
genotype) are shown with means and standard deviations. Statistical difference was tested by 
Student's t-test. (C) A volcano plot showing differentially expressed genes between Cd2ap-
deficient (KO, n=2) and -sufficient (WT, n=2) TFH cells harvested from mixed BM chimeras 22 








Fig 2.10. Cd2ap-deficiency causes sustained TCR signaling specifically in TH1 cells in 
vitro.(A) Schematic of experimental strategy for culture of CD4 T cells. (B) Concentration of 
IFN-γ or IL-4 in supernatant measured by ELISA 24 hours after re-stimulation of polarized 
Cd2apF/F and Cd4-cre+ Cd2apF/F TH1 cells and TH2 cells with plate-bound anti-CD3/anti-CD28 
antibodies. (C) Immunoblotting showing phosphorylation of MEK1/2 in polarized Cd2apF/F and 
Cd4-cre+ Cd2apF/F TH1 or TH2 cells following re-stimulation with plate-bound anti-CD3/anti-
CD28 for the indicated times at 37˚C. Anti-CD2AP, -CIN85 and ERK were used as control. Data 
are representative of three experiments. (D) Downregulation of surface TCR of Cd2apF/F and 
Cd4-cre+ Cd2apF/F T cells that were polarized under indicated conditions. Cells were stimulated 
with plate-bound anti-CD3 and surface TCR levels were quantitated at the indicated time points. 
Data are representative of three experiments. (E, F) Intracellular staining for IFN-γ and TNF-α of 
polarized Cd2apF/F and Cd4-cre+ Cd2apF/F TH1 cells after re-stimulation with PMA and 
Ionomycin or plate-bound anti-CD3 and anti-CD28 for 4 or 24 hours in the presence of Brefeldin 
A for the last 2 hours before harvest. Representative plots (E) and statistical analyses with means 





Fig 2.11 Intact CD8 and CD4 T cell response to LCMV Armstrong in T cell-specific Cin85 
deficient mice. (A) Expression of IFN-γ, TNF-α, and IL-21 in splenocytes from day 8 LCMV-
Armstrong following stimulation with gp61-80 peptide in Cin85F/F and CD4-cre+ Cin85F/F 
animals (B) Expression of CD4, CD8, and CD44, and binding of H-2Db(gp33-41) and H-
2Db(np396-404) tetramers of splenocytes from Cin85F/F and Cd4-cre+ Cin85F/F mice eight days 
after LCMV-Armstrong infection. (C) Expression of CD19, B220, GL7, and Fas eight days after 
LCMV-Armstrong infection in Cin85F/F and Cd4-cre+ Cin85F/F mice (D, E) Absolute 
quantification of cell numbers from Cin85F/F and Cd4-cre+ Cin85F/F mice. Data are representative 






Fig 2.12. Delayed clearance of LCMV-c13 in Vav1-icre Cin85F/F mice.(A) Plasma viral 
abundance of LCMV determined by gp transcripts in Cin85F/F and Vav1-icre+ Cin85F/F. (B-D) 
Frequencies and absolute numbers of (B) H-2Db(gp33-41)-specific CD8+ cells (C) I-Ab(gp66-
77)-specific CD4 T cells and CXCR5+ PD-1+ CD4 T cells, and (D) Fas+ GL7+ B cells in the 
spleen day 30 post-infection in LCMV-c13 infection in Cin85F/F and Vav1-icre+ Cin85F/F mice. 







Fig 2.13 Cin85-Deficiency results in defective clearance of LCMV-c13 and is correlated with 
decreased neutralizing antibody titer.(A, B) Analysis of LCMV abundance in plasma in Cin85F/F 
and Cd4-cre+ Cin85F/F mice as determined by LCMV gp transcript levels (A) or focus forming 
assay (B) at day 80. Horizontal lines indicate median. The limit of detection is shown by dashed 
lines. Statistical significance was tested by Mann Whitney U-test. (C) Frequencies of Fas+ GL7+ 
B220+ GC B cells at day 35 after LCMV-c13 infection. (D) anti-LCMV IgG antibody titers of 
plasma from Cin85F/F and Cd4-cre+ Cin85F/F mice 30 days after LCMV-c13 infection. (E) 
Neutralizing activity of plasma from Cd2apF/F and Cd4-cre+ Cd2apF/F mice 80 days after LCMV-
c13 infection. Reduction in focus forming units (FFU) in the presence of 1:5 dilution of plasma 
compared to untreated control (% Neutralization) is shown with mean and standard deviation. 




























In response to persistent exposure to antigen, CD8 T cell responses are attenuated in part 
due to upregulation of the inhibitory receptor PD-1. PD-1 mediated inhibitor signaling on T cell 
responses has been associated with prolonged viral persistence or tumor progression, and 
blockade of PD-1 signaling during antigen persistence can lead to durable responses. However, it 
remains elusive whether PD-1-mediated signaling directly promotes viral persistence via 
suppression of immune responses or if it functions as a mechanism by which the host facilitates 
durable immunity by preventing tissue damage. Here we show that PD-1-mediated suppression 
is required for durable CD8 T cell responses against chronic viral infection. Treating mice 
infected by a chronic strain of LCMV with PD-1 blockade at the peak of viremia does not cause 
fatal immunopathology, but eventually resulted in disruption of lymphoid architecture and a 
reduction in the CD8 T cell response. Furthermore, transient blockade of type-I interferon 
completely prevented death of LCMV-infected mice treated with PD-1 blockade at the time of 
infection by attenuating CD8 effector function and, intriguingly a combination of the transient 
blocking IFNAR signaling and delayed PD-1 blockade, which alone would compromise antiviral 
immunity, accelerated viral clearance without causing immunopathology. These results indicate 
that harnessing CD8 T cells at early stages of chronic viral infection in paradoxically benefits 









 The host immune system responds to invading pathogens through a variety of effector 
mechanisms that not only control infection but also have the potential to cause host damage and 
the manifestations of disease 1. The adaptive immune response is elicited following engagement 
of antigen receptors on B and T cells along with co-stimulatory signals and cytokines which 
activate a dynamic gene expression program necessary for clonal expansion and effector 
differentiation of antigen-specific naive T and B cells 2,3.  While robust adaptive responses often 
achieve clearance of pathogen, prolonged persistence of infections in the host in turn results in 
deregulated CD8 T cell responses known as T cell “exhaustion”, which is characterized by 
increased expression of PD-1 and other inhibitory receptors4,5 and decreased ex vivo cytokine 
production. A similar phenomenon is observed within the tumor microenvironment; tumor 
infiltrating lymphocytes (TIL) express inhibitor receptors in the presence of persistent antigen. 
These situations highlight a fundamental mechanism of T cell suppression involving 
extracellular modulation of intracellular signaling pathways.  
The PD-1 pathway was originally found to be involved in T cell apoptosis and cell death 
in a variety of in vitro experiments 6, however, later, it was found to play a role in regulation of T 
cell priming in vivo 7,8. Early studies revealed PD-1 to act in an inhibitory fashion; its loss 
promoted T cell priming and activation. These studies were consistent with genetic loss of PD-1 
or its ligands PD-L1/L2 which results in varying degrees of autoimmunity depending on the 
strain of mice 9,10. Thus, PD-1 became a canonical inhibitory molecule which acted to suppress T 
cell responses during T cell activation and also to a certain extent in peripheral tissues in 




of PD-1 which serves to recruit SHP-2 phosphatase to inhibit signaling via the CD28-B7 
pathway and/or direct inhibition of TCR signaling.  
A significant body of evidence has implicated the PD-1 pathway in tumor control. 
Overexpression of PD-L1 in certain tumor lines was shown to promote tumor growth in a T cell 
dependent manner, and genetically deficient mice have reduced tumor burden in some models 
11,12. The role of PD-L1 expression on host or tumor depend on a variety of factors, specific to 
each tumor type, and highlight the multifaceted role PD-1 plays in the antitumor response 13-15. 
These studies led to the development of checkpoint blockade inhibitors in the clinic, which have 
resulted in significant and durable effects in a subset of patients with metastatic cancer. While 
the effects of checkpoint blockade are clear, a mechanistic understanding of how the immune 
response is altered remains not as well understood.  Specifically, the relevance to T cell priming 
and “reinvigoration” of exhausted T cells is not known.  
Chronic viral infections result in prototypic T cell “exhaustion” whose molecular and 
cellular basis has been a subject of intense investigation. It is generally thought development of 
high-affinity neutralizing antibodies function in conjunction with CD8 T cell responses are 
required for significant viral control.  Infection of mice with rapidly-replicating LCMV strains 
results in CD8 T cell exhaustion and a long-term viremia that can be eventually cleared 
depending on dose and strain of both mouse and virus 16-18. A mechanistic link to T cell 
exhaustion and viral persistence is exemplified by the inhibition PD-1:PD-L1 interactions which 
leads to so-called “re-invigoration” of CD8 T cells and enhanced control of viremia in certain 
settings19-21 . Alternatively, acquisition of the exhausted state may be an adaptation strategy 
taken by the host, which eventually allows for durable control of persistent antigen without 




PD-1-mediated suppression of T cell responses are subject to modulation by host factors which 
remain incompletely defined. 
In response to infection by LCMV clone 13, a variant stain of LCMV-Armstrong causing 
chronic infection, CD8 T cells upregulate PD-1 expression by day 5 after infection and continue 
to express PD-1 until virus is spontaneously cleared in C57BL/6 mice around days 80-100 after 
infection22 . However, the role of PD-1 during the establishment of exhaustion remains 
incompletely understood in part due to fatal immunopathology caused by blocking PD-1 
interaction with its ligand PD-L1 during LCMV infection 19,23. It should be noted that death due 
to rapidly-replicating LCMV can also be caused by mechanisms other than blockade of PD-1 as 
evidence by death of certain strains of mice, and with treatment with exogenous IL-21 18,24 . 
Nevertheless, this lethal phenotype has been attributed to a consequence of high viral load as it 
does not occur in LCMV-Armstrong infected mice. However, death does not occur following 
PD-L1 blockade during chronic phase of the infection (>23) or in the context of CD4 T cell 
depletion (>D45) in which viral load is extremely high indicating PD-L1 blockade is not 
sufficient to cause death in all contexts. 
In this work, we sought to clarify the function of PD-1 throughout the course of LCMV-
c13 infection in mice. We establish that the function of PD-1 during the late acute phase (D8-22) 
is required for durable control of infection, in contrast to its function in the chronic phase (>23) 
where it promotes viral persistence. Importantly, we find that although PD-1 protects the animal 
from death immediately following infection, this is not clearly the case following acute 
inoculation, potentially a reflecting a specific phenomenon during the T cell priming phase. We 
found evidence of diminished adaptive immune responses correlated with tissue damage induced 




combination blockade with anti-PD-L1 accelerated viral clearance. These results suggest the 










PD-L1 blockade at peak of viremia results in enhanced CD8 T cell response but not 
significant lethality  
 To understand the difference in phenotype observed between blockade of the PD-1 
pathway late in LCMV-c13 infection compared to infection of PD-1 or PD-L1 deficient mice, we 
first tested whether this effect could be trivially explained by incompleteness of PD-1 blockade. 
A previous report using antibody blockade at the beginning of infection reported significant core 
body temperature loss, however, did not measure lethality. Using two different antibody 
treatment strategies: 200ug everyday for 5 days or 200ug every other day for 8 days (data not 
shown) we observed complete lethality of treated mice 10 days after infection (Fig. 1A) .Thus, 
antibody mediated blockade is sufficient to induce lethality following LCMV-c13 infection 
recapitulating previously reported genetic knockout experiments.   
 While blockade of the PD-1 pathway “reinvigorates” exhausted T cells, it has also been 
implicated in early phases of T cell priming 7,8. Another possibility is that loss of PD-1 signaling 
prevents exhaustion, resulting in a more “pathogenic” phenotype. However, the prevention of 
exhaustion is likely not the case as competitive transfer experiments of WT and PD-1 deficient T 
cells into the same environment, paradoxically results in enhanced exhaustion25. We thus, 
analyzed the PBMC of mice at Day 5 of infection, before the mice exhibit signs of disease, and 
found that anti-PD-L1 treated mice had an increased frequency of both CD8 T cells and LCMV-
specific CD8 T cell compared to control mice (Fig. 1, B and C). This result indicates that PD-1 
deficiency at the beginning of infection results in enhanced priming and accumulation of 




 As previously mentioned, blockade of the PD-1 pathway following infection with acute 
strains of LCMV such as WE and Armstrong does not result in lethality dependent on CD8 T 
cells. This difference is likely due to the vastly different viral loads attained with greater than 105 
PFU/mL of serum with LCMV-c13 and <102 PFU/mL with the acute strains. Thus, a commonly 
held view is that a high viral load in the context of PD-1 deficiency is sufficient to induce lethal 
disease19,23 . We tested this hypothesis directly by blocking PD-L1 (200ug every third day) 
beginning on Day 8, at the peak of viremia. Treatment beginning at Day 8 did not result in 
significant mortality, with >80% of mice surviving the course of treatment (Fig. 2A). Thus, 
blockade of the PD-1 pathway at this time point is not sufficient to induce lethality after Day 8, 
similar to results obtained with blockade beginning at Day 2319 . 
 It is possible that micro-environmental factors prevent PD-L1 induced lethality or 
decrease efficacy of blockade which could explain our results. We thus wished to test whether 
the CD8 T cells could still mediate significant lethality. To determine if this was the case, we 
transferred CD8 Effector T cells from mice infected with the acute LCMV-Armstrong strain into 
Day 8 LCMV-c13 infected mice, and treated with anti-PD-L1. We found that anti-PD-L1 
treatment along with transferred CD8 T cells induced lethality in 2-5 days. We conclude that 
efficacy of blockade is not impeded by microenvironmental factors affecting antibody 
administration but rather alteration of host CD8 T cell response in a cell-intrinsic or extrinsic-
manner (Fig. 2B).  
 We were next interested in determining how PD-L1 blockade at Day 8 affected the 
adaptive immune response. Analysis of PBMC at Day 14 of infection revealed significant 
expansion of bulk and antigen-specific T cells in PD-L1 treated mice (Fig. 3, A and B). LCMV-




TCR-dependent activation (Fig. 3B). Consistent with an increased CD8 T cell response we found 
that treated mice did not begin to re-gain weight following after the initiation of blockade at Day 
8 (Fig. 3C), suggesting that immunopathological disease was enhanced. Correspondingly, we 
found increased ALT activity in the serum of treated mice, a marker of liver damage mediated by 
CD8 T cells (Fig. 3D). When we measured viral load in the serum at Day 14, we found them to 
be comparable (Fig. 3E). Thus PD-L1 blockade beginning at Day 8 results in a non-fatal 
immunopathology, with no significant alteration of viral load.  
 We were then interested in determining the resultant effects following two weeks of 
blockade initiated on Day 8. In contrast to the expanded antigen-specific cells at Day 14, we did 
not observe significant differences in the PBMC at Day 22 (Fig. 4, A and B). However, gp33-
specific cells did express higher amounts of PD-1 and LAG-3 consistent with enhanced 
activation (Fig. 4, A and B), also observed on Day 14. The high levels of PD-1 suggested T cells 
were still in a environment with persistent antigen; we found no statistical difference in viral load 
compared to control (Fig. 4C). These results indicate release from PD-1 promotes a temporary T 
cell expansion that quickly contracts back to control levels and importantly does not significantly 
impact viral load.  
  To more closely assess the effect of anti-PD-L1 blockade initiated on Day 8 we analyzed 
the spleens of mice immediately at the end of treatment at Day 22. Grossly, we observed a 
significant reduction in spleen size in anti-PD-L1 treated mice (Fig. 5A) . This size difference 
was also reflected in total splenocyte number which was reduced by 2 fold compared to control.  
(Fig. 5B). Given that CD8 T cells mediate significant damage to lymphoid tissue early in 
LCMV-c13 infection, these results indicate PD-L1 blockade potentiates this effect. Consistent 




we found similar results in the spleen at this timepoint (Fig 5, C and D). However, given the 
reduction in splenocyte number, absolute numbers of CD8 T cells were reduced (Fig. 5, C and 
D). Previous reports have suggested loss of PD-1 signaling to promote loss of a T cell progenitor 
pool in a cell-intrinsic manner26-29.  To assess if this was the case following treatment, we 
analyzed the TCF1+ progenitor gp33-specific pool using flow cytometry and did not observe any 
differences in frequency between control and treated mice (Fig. 5C). When we measured PD-1 
expression on the progenitor-like TCF-1+ and terminal Tim-3+ subset we found higher 
expression in anti-PD-L1 treated mice consistent with increased activation on both subsets (Fig. 
5E). These results suggest that in the context of blockade of PD-L1 the CD8 T cell response is 
able to maintain a progenitor-like pool of cells and could be having an impact on both 
populations.  
 Our results suggested that following treatment CD8 T cells were activated, as determined 
by increased PD-1 expression, but could not accumulate in a durable manner. In support of 
continued activation that was ongoing at Day 22, we found increased frequency of gp33-specific 
Ki-67+ cells in anti-PD-L1 treated mice compared to control (Fig. 6A). In addition, following ex 
vivo stimulation with gp276-284 peptide we found an increased frequency of IFNg+ and 
IFNg+ TNFa+ cells (Fig. 6B). These results suggest the CD8 T cell response is enhanced 
following blockade, however, its functional impact is unclear.  
 Given the role of PD-1 in preventing tissue damage, and our results we hypothesized 
unleashed CD8 T cell responses would negatively impact other arms of the immune response. 
We thus analyzed the germinal center response at Day 22 and found significantly reduced 




revealed reduced follicle size and irregular borders between follicle and red pulp in treated mice 
(Fig. 7B). We suspect CD8 T cell mediated cytokine secretion of direct killing could lead to 
altered stromal compartment and indirectly or directly affect the B cell response.  
  To test if the reduction in CD8 T cell response was cell-intrinsic we performed a transfer 
of PD-1+ cells from control and anti-PD-L1 treated mice, into congenic recipients, followed by 
LCMV-c13 infection (Fig 8A). Importantly, we did not observe any differences in the expansion 
of transferred cells assessed by frequency of CD45.2 cells in the PBMC on Day 8 after infection 
(Fig. 8B).  
We were next interested in determining the mechanism underlying the detrimental 
consequences of PD-1 blockade. Kamphorst et al., found that the reduction in viral load and CD8 
T cell expansion following PD-1 blockade was completely dependent on CD28-B7 mediated 
signaling in the context of CD4 depletion20 . However, it cannot be ruled out that PD-1 also 
directly inhibits TCR dependent signaling and thus co-stimulation independent cytokine 
secretion or perforin mediated killing. To test these ideas, we treated mice at Day 8 with anti-PD-
L1 along with anti-B7 to assess the CD28 dependency of PD-L1 blockade. We analyzed the 
spleens of mice after two doses of antibody injection on Day 14.  Similar to analysis at Day 22, 
the spleens from anti-PD-L1 treated mice at Day 14 were significantly smaller, also reflected in 
the total splenocyte number (Fig. 9A). However, the absolute number gp33-specific cells were 
increased consistent with the incrased frequency in the PBMC at this time point (Fig. 9, B and 
C). Importantly, co-blockade of PD-L1 and B7 also resulted in significantly lower number of 
splenocytes suggesting anti-PD-L1 blockade mediates a detrimental effect on total spleen 
number independent of B7 signaling (Fig. 9, B and C). B7 was efficacious as the number of 





 The decreased splenocyte number suggested that blockade of PD-1 inhibits not only 
CD28 but also another pathway in vivo. Given that PD-1 expression is directly induced by the 
TCR, we suspect TCR-dependent signaling is also directly inhibited as we noted increased PD-1 
expression on gp33-specific T cells following treatment both anti-PD-L1 single treatment and 
anti-PD-L1/anti-B7 combined treatment (Fig. 9D).  We thus suspect enhanced cytokine 
secretion, IFNg or TNFa, or direct perforin-mediated cytotoxicity could be contributing to loss 
of spleen size due to effects on stromal cells.  
 The detrimental effect of anti-PD-L1 on the adaptive immune response suggested to us 
that there could be a loss of viral control after the cessation of blockade. Indeed, we observed at 
later time points beginning on Day 37 significantly higher viral loads in the serum in anti-PD-L1 
treated mice (Fig 10A). By Day 80 when most control mice had resolved viremia, a majority of 
anti-PD-L1 mice still exhibited high viremia (Fig. 10A). As a control, we treated mice with anti-
PD-L1 from Day 23-37 and as expected observed accelerated control of virus in the serum (Fig 
10A). Our results indicate that the functional outcome of PD-L1 blockade has divergent effects 
depending on the timing in infection.  
 To help understand how blockade from Day 8-22 could have a substantial lasting impact 
on viral control following cessation of treatment we analyzed the PBMC of mice at Day 37. We 
detected a significant reduction in total CD8 T cell frequency and gp276-tetramer binding T cells 
in the blood in anti-PD-L1 treated mice at this time-point (Fig. 10, B and C). Importantly, we 
observed an increase in gp276 cells compared to control in mice treated with anti-PD-L1 




Day 80 of infection, we found continued loss of CD8 T cells in the blood in viremic mice that 
received anti-PD-L1 treatment from Day 8-22 (Fig. 10D).  
To determine lasting consequences of PD-L1 blockade from Day 8-22 we performed 
flow Cytometry of splenocytes at Day 37. We found there to be decreased total splenocytes, but 
a preserved frequency of CD8 T cells and gp33-specific T cells (Fig 11, A and B). However, we 
did find an increased frequency of Tim-3+ gp33-specific cells (Fig 11C). Tim-3+ cells have been 
termed “terminally exhausted”, which could reflect an intrinsic dysregulation of cells, or also an 
extrinsic alteration which promotes their accumulation following blockade. Nevertheless, the 
data indicate a detrimental effect on the CD8 T cell response well-after cessation of blockade.  
Importantly, the frequency of TCF1+ stem-cell like cells at this time point was similar, 
suggesting this pool is protected from depletion in the context of PD-L1 blockade. Previously, it 
was shown genetically PD-1 deficient T cells were depleted of the Tbethi population, however, 
under our treatment regimen we found a nonsignificant trend toward a decrease in the Tbethi 
population (Fig. 11C). As a whole, our data point toward CD8 T cell mediated disruption of 
lymphoid organs, that in a cell-extrinsic manner diminishes the adaptive immune response 
resulting in a long-term viremia.  
 We next wondered whether we could potentially separate the protective versus 
pathological effects of the CD8 T cell response mediated by blockade of the PD-1 pathway. We 
hypothesized modulators of the cytokine microenvironment could either influence T cell 
differentiation or the effect T cells have on tissue. Type I Interferon has a well-established role in 
the induction of genes that directly inhibit viral activity, however, it also promotes 
immunopathology in certain settings18. anti-IFNAR at the beginning of infection, paradoxically 




interferon induces known immunosuppressive genes such as IL-10 and PD-L1. In addition, Type 
I interferon has been shown to facilitate effector differentiation of T cells in an intrinsic-manner, 
promoting both cytokine secretion and cytotoxicity.  
We thus first wished to more closely examine the response of Ifnar–/– mice to LCMV-c13 
infection. At Day 8 following LCMV-c13 infection IFNAR deficient mice exhibited increased 
spleen size, and increased splenocyte number compared to control (Fig. 12A). However, we 
found decreasd frequency of CD8 T cells and gp33-specific T cells in the spleen consistent with 
an impaired T cell response (Fig 12, B and C). As previously reported, we found a increase in 
frequency of TCF1+ cells and decrease in Tim-3+ cells within gp33 specific cells (Fig 12, B and 
C).  . The combined effect however, indicated, that the TCF1+ gp33-pool of cells was similar in 
absolute number (Fig 12D) between WT and IFNAR deficient animals, with a severe reduction 
in Tim-3+ cells which express perforin and granzyme and likely contribute to 
immunopathological damage. When we measured PD-L1 expression on APC populations we 
found there to be an approximately 2 fold decrease in gMFI within CD11c+MHC-II+CD11b+ 
“dendritic cells” (Fig 13, A and B). However, this reduction was relatively modest in 
comparison to total amount of PD-L1 present on the splenocytes.  
  
 To determine if immunopathological damage and/or lethality caused by PD-L1 blockade 
required Type I Interferon, we treated mice with an anti-IFNAR (MAR1) antibody following 
infection. We administered 1mg of anti-IFNAR 1 day before LCMV-c13 infection and treated 
with mice with anti-PD-L1 every other day for 8 days. We observed an almost complete rescue 




lethality by Day 10 (Fig. 14A). The role of Type I Interferon in LCMV-c13 includes both 
induction of PD-L1 and IL-10, we tested whether blockade of IL-10 could also rescue anti-PD-
L1 induced lethality. When we treated mice with anti-IL-10R and anti-PD-L1, the mice exhibited 
complete lethality similar to anti-PD-L1 alone (Fig 14B). Thus, the function of Type I IFN in 
inducing lethality appears to be independent of IL-10 induction in this setting.  
Similar to results obtained in the spleen at Day 8 in IFNAR deficient mice, we found a 
decreased frequency of CD8 T cells and gp33-specific cells in anti-IFNAR treated mice (Fig 15, 
A and B). While blockade of IFNAR reduced PD-L1 expression on DCs and macrophages, we 
found anti-IFNAR/anti-PD-L1 double blockade to still expand gp33-specific cells suggesting 
significant PD-L1 mediated signaling was still ongoing (Fig 15, A and B). The expression of 
PD-1 was significantly higher in anti-IFNAR and with combined treatment, potentially 
indicating higher viral load or an intrinsic effect on PD-1 expression. Consequently, we 
measured viral burden at Day 8 of the infection anti-IFNAR treated mice had ~5 fold higher viral 
load compared to control (Fig 15C) likely reflecting lack of antiviral gene induction, which 
could explain higher PD-1 expression. Notably, increased viral load was also observed in mice 
with combined anti-IFNAR/anti-PD-L1 treatment on Day 8, suggesting enhanced CD8 T cell 
responses are unable to effectively control virus in this setting (Fig 15C).  
We were next interested in determining the effect of combined treatment on long-term 
viral control. As expected, we found enhanced viral clearance at Day 22 of infection in anti-
IFNAR treated mice compared to control (Fig 15C). However, the combined treatment also 
exhibited enhanced clearance compared to control at Days 22 and 37, but was not significantly 




 Given the rescue of lethality with anti-IFNAR blockade, we next tested with anti-IFNAR 
blockade could rescue the detrimental effect of PD-L1 blockade initiated on Day 8. Indeed, we 
found blockade of IFNAR at the beginning of infection and anti-PD-L1 treatment  on Days 8-22 
resulted in lower viral loads compared to mice treated with anti-IFNAR alone (Fig 16A). 
Consistent with enhanced viral clearance, the splenic reduction caused by anti-PD-L1 treatment 
alone was reversed with combined anti-IFNAR (Day -1) and anti-PD-L1 Day8-22 (Fig 16, B 
and C). We suspect the effect of IFNAR on the host could be multi-factorial; diminished CD8-
intrinsic signaling results in a diminished CD8 response, and non-hematopoietic tissues are 






Herein we demonstrate a critical function of PD-1 mediated restriction of CD8 T cells 
required for induction of protective immunity. At early time points, Enhanced activation of CD8 
T cells could be elicited with blockade of PD-L1 however, however, viral load was not altered 
and instead damage to the host was observed.  Blockade of Type I Interferon both abrogated 
lethality and promoted viral clearance in the context of PD-1 blockade. Our results suggest 
manipulation of the host microenvironment can ameliorate detrimental consequences of 
checkpoint blockade while preserving the beneficial aspects; a current issue with cancer 
immunotherapy. 
Enhanced clearance is observed anti-PD-L1 administered over the course of 2 weeks 
beginning on Day 23 of infection. Moreover, a similar effect is observed in a well-established a 
model of persistent infection throughout the life of the animal by depletion of CD4 T cells at the 
beginning of infection. Enhanced viral control is associated with increased antigen-specific CD8 
T cell numbers and ex vivo cytokine production (likely reflecting increase LCMV-specific T 
cells).  What explains the difference in outcome in outcome following treatment with blockade 
beginning at Day 8? These scenarios are likely different from early time-points (Day0-15) after 
the infection as the cytokine and co-stimulation in the microenvironment are substantially 
lower32. Thus, while PD-1 acts as a dominant negative regulator of T cell function, this serves to 
dampen activation signals from the microenvironment which promote T cell pathogenicity. 
However, when cytokine and co-stimulation signals wane, release of PD-1 signaling improves 
viral control without causing significant tissue damage.  
We have now defined three phases of the infection in which PD-1 can be considered to 




failure caused by damage to the lung. From Day 8-22, PD-1 prevents damage to lymphoid 
organs, and thus the adaptive immune response which ultimately is required for viral control. 
Following this period, PD-1 acts in a negative fashion, with its blockade promoting viral 
clearance.  
Importantly, it appears the blockade of PD-1 is not required for viral clearance. 
Immunocompetent mice can clear the virus without administration of blockade suggesting the 
host engages other mechanisms to sustain a durable immune response. In the context of CD4 
depletion, the reduction of viral load is transient, and rebounds to similar levels following 
blockade. Given that PD-1 expression is very-well correlated to presence of antigen, it is unclear 
how T cells would modulate their levels in an ongoing immune response to achieve a 
physiologic effect. In addition, PD-L1 is constitutively expressed, and while Type I and II 
Interferons can increase expression in certain cell types, it appears the functional relevance is 
unclear. Thus one way to conceptualize the PD-1 pathway is strictly that of a tolerance enforcer. 
The danger of immunopathological damage is a stronger evolutionary pressure then enhanced 
clearance of virus on the order of weeks. Given that chronic viral infections also require 
significant help from the B cell response in the form of high-affinity neutralizing antibodies, 
enhancing CD8 T cell responses as a single modality is likely not to have significant therapeutic 
benefit, unless the clearance process is already initiated.  
Our results have potential implications for checkpoint blockade therapy in cancer. 
immune related adverse events (IRAEs) to checkpoint blockade is a significant problem to 
successful therapy. It is possible blockade of Type I Interferon, or other immune signaling 
pathways could selectively inhibit these adverse events, while preserving therapeutic benefit. 




response to the tumor. The function of Type I Interferon has typically been associated with 
enhanced CD8 T cell priming33,34, which is of unclear relevance to checkpoint blockade therapy 
in human tumors. When viewed from a different angle, targeted cytokine therapy into the tumor 
microenvironment could boost responses to checkpoint blockade. Overall, our results indicate 
that while the PD-1 pathway acts a strong inhibitor of T cell function, its pliability is subject to 





3.5 MATERIALS AND METHODS 
Mice and Infection 
Male C57BL/6N and B6-CD45.1 mice were purchased from Charles River Laboratory. Ifnar–/–
mice were obtained from Jackson Laboratories. To generate BM chimeras, B6-CD45.1 mice 
were lethally irradiated (10.5 Gy) and reconstituted with donor BM cells for at least 8 weeks 
before experiments. All mice were housed in a specific pathogen-free facility at Washington 
University in St. Louis, and were analyzed at 8 to 10 weeks of age, unless stated otherwise. All 
experiments were performed according to a protocol approved by Washington University’s 
Animal Studies Committee.  
Mice were infected with 2 x 105 plaque-forming units (PFU) of LCMV-Armstrong strain 
via the intraperitoneal route or 2 x 106 (PFU) of LCMV-c13 by intravenous injection. For the 
quantification of plasma viral load, RNA was extracted from 10 µL of plasma using Trizol (Life 
Technologies). Before RNA extraction a spike-in of RNA extracted from 293T cells expressing 
gfp mRNA was added to the plasma samples. The amounts of the LCMV gp transcript relative to 
that of ‘‘spiked- in’’ gfp RNA were determined by real-time qRT-PCR as previously described 
(Chou et al., 2014; McCausland and Crotty, 2008)  
Adoptive Transfer 
 CD8 T cells were positive selected using Flow Comp Dynabeads (Thermo Fischer) using 
the manufacturer’s suggested protocol. The indicated number of cells were transferred 





a-PD-L1 (BioXcell, 29F.1.G2) was used at 200ug per dose. Anti-IFNAR (MAR1, Leinco) was 
used at 1mg per dose given at the indicated time. Anti-IL-10R (BioxCell, 10B.A2) was used at 
500ug per dose at the indicated days.  
Histology 
Organs were fixed in 4% PFA overnight, then dehydrated in 70% ethanol. Samples were subject 
to H&E staining using standard methods performed by the Developmental Biology Histology 
Core at Washington University in St. Louis.  
ALT Assay 
ALT measurement was made using Sigma ALT Serum Kit using manufacturer’s 
recommended instructions.  
Cell Preparation and Flow Cytometry 
Single-cell suspensions were prepared by manual disruption of spleens with frosted glass 
slides followed by removal of debris through 80 micron nylone mesh. Absolute cell counts were 
determined using Vi-Cell (Becton-Dickson). The following flourochrome-conjugated antibodies 
were purchased from Biolegend, BD, or Thermo Fisher. Anti-Rabbit IgG-A488 (Thermo 
Fischer). Intranuclear staining was performed using Foxp3 Fixation/Permeabilization Kit 
(Thermo Fischer) according to manufacturer’s protocol.  
Intracellular Cytokine Staining  
 Splenocytes were stimulated with 1ug/mL of gp33 or gp276 peptide for 2 hours before 




antibody staining, followed by LIVE/DEAD Aqua staining (Thermofisher) for 30 minutes at 4˚C 
before being fixed with 4% PFA for 10 minutes at RT. Cells were washed twice with 0.03% 
saponin in 2% FBS/PBS before being stained with the indicated antibodies in 0.3% Saponin in 






 We thank the NIH tetramer core facility at Emory for LCMV-gp66-77 tetramer. We thank 





3.7 AUTHOR CONTRIBUTIONS 
Conceptualization: Saravanan Raju, Takeshi Egawa. 
 Data curation: Saravanan Raju, Daniel J. Verbaro 
 Formal analysis: Saravanan Raju, Takeshi Egawa 
 Funding acquisition: Takeshi Egawa. 
 Investigation: Saravanan Raju, Takeshi Egawa. 
 Project administration: Takeshi Egawa. 
 Resources: Takeshi Egawa. 
 Supervision: Takeshi Egawa. 
 Writing ± original draft: Saravanan Raju, Takeshi Egawa. 













1. Rouse, B. T. & Sehrawat, S. Immunity and immunopathology to viruses: what decides the 
outcome? Nature Reviews Immunology 10, 514–526 (2010). 
2. Chang, J. T., Wherry, E. J. & Goldrath, A. W. Molecular regulation of effector and 
memory T cell differentiation. Nat Immunol 15, 1104–1115 (2014). 
3. Hoffman, W., Lakkis, F. G. & Chalasani, G. B Cells, Antibodies, and More. Clinical 
Journal of the American Society of Nephrology 11, 137–154 (2016). 
4. Wherry, E. J. & Kurachi, M. Molecular and cellular insights into T cell exhaustion. Nature 
Reviews Immunology 15, 486–499 (2015). 
5. Speiser, D. E. et al. T cell differentiation in chronic infection and cancer: functional 
adaptation or exhaustion? Nature Reviews Immunology 14, 768–774 (2014). 
6. Dong, H. et al. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential 
mechanism of immune evasion. Nature Medicine 1–8 (2002). doi:10.1038/nm730 
7. Keir, M. E., Freeman, G. J. & Sharpe, A. H. PD-1 Regulates Self-Reactive CD8 +T Cell 
Responses to Antigen in Lymph Nodes and Tissues. J.I. 179, 5064–5070 (2007). 
8. Butte, M. J., Keir, M. E., Phamduy, T. B., Sharpe, A. H. & Freeman, G. J. Programmed 
Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T 
Cell Responses. Immunity 27, 111–122 (2007). 
9. Nishimura, H. et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient 
mice. Science 291, 319–322 (2001). 
10. Nishimura, H., Nose, M., Hiai, H., Minato, N. & Honjo, T. Development of lupus-like 
autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying 




11. Iwai, Y. et al. Involvement of PD-L1 on tumor cells in the escape from host immune 
system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 99, 
12293–12297 (2002). 
12. Iwai, Y., Terawaki, S. & Honjo, T. PD-1 blockade inhibits hematogenous spread of poorly 
immunogenic tumor cells by enhanced recruitment of effector T cells. International 
Immunology 17, 133–144 (2005). 
13. Juneja, V. R. et al. PD-L1 on tumor cells is sufficient for immune evasion in 
immunogenic tumors and inhibits CD8 T cell cytotoxicity. J Exp Med 214, 895–904 
(2017). 
14. Noguchi, T. et al. Temporally Distinct PD-L1 Expression by Tumor and Host Cells 
Contributes to Immune Escape. Cancer Immunol Res 5, 106–117 (2017). 
15. Lau, J. et al. Tumour and host cell PD-L1 is required to mediate suppression of anti-
tumour immunity in mice. Nat Comms 8, 14572–11 (2017). 
16. Moskophidis, D., Lechner, F., Pircher, H. & Zinkernagel, R. M. Virus persistence in 
acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T 
cells. Nature 362, 758–761 (1993). 
17. Matloubian, M., Concepcion, R. J. & Ahmed, R. CD4+ T cells are required to sustain 
CD8+ cytotoxic T-cell responses during chronic viral infection. J. Virol. 68, 8056–8063 
(1994). 
18. Oldstone, M. B. A. et al. Lymphocytic choriomeningitis virus Clone 13 infection causes 
either persistence or acute death dependent on IFN-1, cytotoxic T lymphocytes (CTLs), 
and host genetics. Proc. Natl. Acad. Sci. U.S.A. 115, E7814–E7823 (2018). 




infection. Nature Publishing Group 439, 682–687 (2006). 
20. Kamphorst, A. O. et al. Rescue of exhausted CD8 T cells by PD-1–targeted therapies is 
CD28-dependent. Science eaaf0683–10 (2017). doi:10.1126/science.aaf0683 
21. Pauken, K. E. et al. Epigenetic stability of exhausted T cells limits durability of 
reinvigoration by PD-1 blockade. Science 354, 1160–1165 (2016). 
22. Wherry, E. J. et al. Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral 
Infection. Immunity 27, 670–684 (2007). 
23. Frebel, H. et al. Programmed death 1 protects from fatal circulatory failure during 
systemic virus infection of mice. J Exp Med 209, 2485–2499 (2012). 
24. Yi, J. S., Du, M. & Zajac, A. J. A Vital Role for Interleukin-21 in the Control of a Chronic 
Viral Infection. Science 324, 1572–1576 (2009). 
25. Odorizzi, P. M., Pauken, K. E., Paley, M. A., Sharpe, A. & Wherry, E. J. Genetic absence 
of PD-1 promotes accumulation of terminally differentiated exhausted CD8 +T cells. J 
Exp Med 212, 1125–1137 (2015). 
26. Im, S. J. et al. Defining CD8+ T cells that provide the proliferative burst after PD-1 
therapy. Nature 537, 417–421 (2016). 
27. Utzschneider, D. T. et al. T Cell Factor 1-Expressing Memory-like CD8+ T Cells Sustain 
the Immune Response to Chronic Viral Infections. Immunity 45, 415–427 (2016). 
28. Wu, T. et al. The TCF1-Bcl6 axis counteracts type I interferon to repress exhaustion and 
maintain T cell stemness. Sci Immunol 1, eaai8593–eaai8593 (2016). 
29. He, R. et al. Follicular CXCR5-expressing CD8+ T cells curtail chronic viral infection. 
Nature 537, 412–428 (2016). 




interferon signaling. Science 340, 207–211 (2013). 
31. Wilson, E. B. et al. Blockade of chronic type I interferon signaling to control persistent 
LCMV infection. Science 340, 202–207 (2013). 
32. Harker, J. A., Lewis, G. M., Mack, L. & Zuniga, E. I. Late interleukin-6 escalates T 
follicular helper cell responses and controls a chronic viral infection. Science 334, 825–
829 (2011). 
33. Diamond, M. S. et al. Type I interferon is selectively required by dendritic cells for 
immune rejection of tumors. J Exp Med 208, 1989–2003 (2011). 
34. Yang, X. et al. Targeting the Tumor Microenvironment with Interferon-&beta; Bridges 







Figure 3.1. a-PD-L1 treatment beginning on Day 0 of LCMV-c13 infection results in 
lethality. (A) (Top) Schematic of treatment regiment (Bottom) Survival curve of mice following 
LCMV-c13 infection (B,C) Flow cytometry analysis (B) and quantification (C) showing 
expression of indicated molecules from PBMC on Day 5 from mice in A. Each symbol 
represents an individual mouse; small horizontal lines indicate the mean (± s.d.). Data are 







Figure 3.2. a-PD-L1 treatment beginning on Day 8 does not result in significant lethality. 
(A) (Top) Schematic of treatment regimen (Bottom) Survival curve of mice following LCMV-
c13 infection, data is partially reproduced from Figure 3.1 (B) (Top) Schematic of transfer and 
treatment regimen for recipient mice (Bottom) Survival curve of mice following adoptive transfer 
of effector CD8+ T cells. Data are combined from at least two independent experiments with n>5 










Figure 3.3. a-PD-L1 treatment beginning on Day 8 results in enhanced CD8 T cell 
responses and disease but not viral control on Day 14. (A,B) FACS plots (A) and 
quantification (B) showing expression of indicated molecules or tetramer binding from PBMC 
on Day 14 after LCMV-c13 infection. (C) Weights of mice following LCMV-c13 infection. (D) 
ALT activity in serum on Day 14 of LCMV-c13 infection (D) Plasma viral load as measured by 
LCMV gp transcript in plasma of mice on Day 14 of LCMV-c13 infection. Each symbol 








Figure 3.4. a-PD-L1 treatment from Day 8-22 results in unaltered viral load and CD8 
Frequencies in PBMC. (A,B) FACS plots (A) and quantification (B) showing expression of 
indicated molecules or tetramer binding from PBMC on Day 22 after LCMV-c13 infection. (D) 
Plasma viral load as measured by LCMV gp transcript in plasma of mice on Day 22 of LCMV-
c13 infection. Each symbol represents an individual mouse; small horizontal lines indicate the 






Figure 3.5 Diminished spleen size and absolute CD8 T cell response following PD-1 
blockade from Day 8-22. (A) Gross Images of spleens from control and anti-PD-L1 treated 
mice 22 days following LCMV-c13 infection. (B) Quantification of absolute number of 
splenocytes from control and anti-PD-L1 treated mice 22 days following LCMV-c13 
infection.(C-E) (C,E) Flow Cytometry of splenocytes from control and anti-PD-L1 treated mice 
at Day 22 of infection (D) Quantification of frequencies and Absolute numbers of the indicated 
cell populations. Each symbol represents an individual mouse; small horizontal lines indicate the 














Fig. 3.6.a-PD-L1 treatment from Day 8-22 results in enhanced CD8 T cell functions at the 
end of treatment. (A) Analysis of Ki-67 expression in gp33-specific CD8 T cells on Day 22. (B) 
Analysis of cytokine production following stimulation of splenocytes with gp276-284 peptide. 









Figure 3.7. a-PD-L1 treatment from Day 8-22 results in a diminished GC response, altered 
splenic architecture. (A, B) Analysis of surface protein expression in B220+ cells. (B) H&E 
staining of spleen and lung sections from Day 22 of LCMV-c13 infection. Each symbol 







Figure 3.8. a-PD-L1 treatment from Day 8-22 does not significantly impact intrinsic CD8 
proliferative capacity. (A) Schematic of experiment in (B). (B) Analysis of CD45.2 frequency 
on Day 8 of PBMC of congenic CD45.1 mice following LCMV-c13 infection. Each symbol 








Figure 3.9 a-PD-L1 induced splenic reduction is B7 independent, but increased PD-1 
expression on CD8 T cells is not. (A-C) Absolute number of splenocytes (A), CD8 T cells (B) 
and gp33-specific T cells (C) on Day 14 of LCMV-c13 infection following treatment initiated on 
Day 8. (D) Expression of PD-1 on gp33-specific CD8 T cells. Each symbol represents an 








Figure 3.10. Long-term defective viral control and diminished CD8 T cell responses 
following a-PD-L1 treatment Days 8-22. (A) Viral load assessed by LCMV gp transcript in 
serum of mice following LCMV-c13 infection. (B, C). Flow cytometry analysis of PBMC on 
Day 37 of LCMV-c13 infection. (D) Flow cytometry analysis of PBMC on Day 80 of LCMV-
c13 infection. Each symbol represents an individual mouse; small horizontal lines indicate the 






Figure 3.11. Accumulation of Tim-3+ cells on Day 37 following PD-1 blockade from days 8-
22. (A-C) (A) FACS plots measuring expression of indicated molecules or binding of tetramer. 
(B) (Left) Absolute number of splenocytes (Right) Quantification of (A). (C) Quantification of 









Figure 3.12 IFNAR deficient mice display increased spleen size, but diminished CD8 T cell 
responses on Day 8 of LCMV-c13 infection. (A) Absolute splenocyte number. (B) Flow 
Cytometry analysis of expression of indicated molecules or tetramer binding (C, D) 
Quantification of  frequency (C) and absolute number (D) of B. Each symbol represents an 





Figure 3.13. PD-L1 expression is slightly reduced on a subset of Dendritic Cells in IFNAR 
deficient animals on Day 8 of LCMV-c13 Infection. (A) Flow Cytometry analysis of 








Figure 3.14. IFNAR but IL-10 signaling is required for a-PD-L1 induced lethality following 
LCMV-c13 infection. (A,B) Survival curves of mice following LCMV-c13 infection. Data are 







Figure 3.15. Diminished CD8 T cell response caused by IFNAR deficiency is rescued by a-
PD-L1 blockade.  (A, B) Flow Cytometry analysis of expression of indicated molecules or 
tetramer binding. (C) Viral load assessed by LCMV gp transcript in serum of mice following 
LCMV-c13 infection.  Each symbol represents an individual mouse; small horizontal lines 







Figure 3.16. a-IFNAR treatment reverses detrimental effects of a-PD-L1 blockade at Day 8 
and enhanced viral clearance. (A) Viral load assessed by LCMV gp transcript in serum of mice 
following LCMV-c13 infection. (B,C) Gross Spleen Size (B), and absolute quantification of 
splenocytes (C) on Day 22 of LCMV-c13 infection. Each symbol represents an individual 



































 CD8 T cell differentiation is characterized by significant phenotypic and functional 
heterogeneity that is likely important for acute pathogen control. However, in chronic viral 
infection, the nature of phenotypic heterogeneity within “exhausted” T cells is much less clear. 
Herein, we perform an in-depth analysis of the CD8 T cell response in chronic viral infection and 
define the behavior of exhausted T cell subsets in vivo. Unexpectedly, in non-competitive 
settings we observe a long-term persistence of “terminally exhausted” Blimp-1+Tim-3+ cells. 
Moreover, we find that TCF-1+ CD8 T cells to exhibit low intrinsic turnover in the context of 
persisting antigen, with “terminally exhausted” Blimp-1+Tim-3+ cells exhibiting significant 
entry into cell-cycle. These results led us to investigate the diversity of CD8 T cells within the 
TCF1– exhausted cells, leading us to define a novel subset of CX3CR1 expressing cells which 
are exclusively found in the TCF1– compartment. Without CD4 T cell help these CX3CR1+ cells 
are selectively depleted and correlated with the accumulation of Tim-3hi cells. We further show 
that IL-21 deficient animals are unable to maintain significant numbers of CX3CR1 expressing 
CD8 T cells and are unable to clear chronic viral infection. These results revise our current 
understanding of T cell exhaustion, and implicate a dynamic regulation of CD8 T cell turnover in 






 CD8 T cells provide pathogen control to the host that is mediated through cytokine 
secretion and direct cytotoxicity 1-3. Signaling through the T cell antigen receptor (TCR) in naïve 
antigen-specific T cells initiates a program of population expansion, and effector differentiation4. 
Following pathogen clearance higher frequencies of antigen-specific CD8 T cells remain as so-
called memory CD8 T cells. This process results in phenotypic heterogeneity of antigen-
experienced CD8 T cells4. Many studies have defined the function of these subsets as defined by 
various cell surface molecules 5. However, the relative contribution of CD8 T cell subsets to both 
pathogen control in the acute and memory phase remains unclear. Importantly, the idea that 
unique subsets divide labor in the immune response has been more recently applied to 
“exhausted” T cells present in chronic infection6-8. However, whether the same principles can be 
directly applied is not abundantly clear.  
 A general paradigm of T cell effector differentiation has emerged from half a century of 
study using acute LCMV-Armstrong as a model infection 9. Antigen-specific CD8 T cell remain 
at increased frequencies compared to naïve mice following resolution of infection and have been 
termed “memory” T cells strictly based on a timepoint >30 days after the acute infection 10. 
However, there is a substantial loss of antigen-specific cells compared to the peak of the 
response; this phenomenon suggested a subset of cells present at the peak of the response were 
“endowed” with memory potential 11. Consequently, Ahmed and colleagues identified IL-7R 
expression at the peak of the response to correlate best with long-lived potential following 
transfer into recipient mice12 . This result forms the basis for discriminating between subsets of T 




(MPEC) and IL7R-KLRG1+ are short lived effector cells (SLEC) 13. While these cells are 
essentially defined by phenotyping markers, and transcription factor expression, their ultimate 
role in the both the acute and memory phase response in the endogenous response has not been 
clear outside of transfer experiments.  
 During the memory phase antigen-specific cells also exhibit significant heterogeneity. 
Lanzavecchia and colleagues established the use of CD62L to distinguish between T Effector 
Memory cells (TEM) and T Central Memory cells (TCM) 14. TEM cells are CD62L– cells that 
exist in peripheral tissues as well as lymphoid organs, while TCM cells are predominant in 
lymphoid organs as their name suggests. Functionally, the most salient difference is that TCM 
cells are able to undergo significantly higher expansion in re-challenge experiments. TEM cells 
are thought to be more “effector-like”, they readily produce cytokines and granzyme, however 
the significance of this depends on type of infection introduced.  
 More recently, several groups have sought to more deeply understand memory T cell 
heterogeneity, which has led to another conceptual shift in our understanding. Specifically, the 
use of CD43 and CD27 has  divided the memory subset into different type of populations than 
simply CD62L 15 16. In addition, the same markers used in the effector phase to identify MPEC 
and SLEC, also have use memory phase. CD127+KLRG1– cells have enhanced proliferative 
capacity following transfer compared to KLRG1+ cells, and tend to persist better 17 18 . In 
summary, there appears to be more than anticipated heterogeneity in cells in the memory phase, 
although a general concept can be derived: cells with higher proliferative capacity and 
persistence generally expression IL7Ra but cannot exert immediate effector activity, and cells 




 An idea that originally did not receive significant attention was the potential for 
“plasticity” or alteration of phenotype between subsets of cells in both late effector phase, and 
during the memory phase. Using KLRG1 and CD127 the frequency of cells with each phenotype 
inverts following infection; KLRG1+ cells are most prevalent early (>60-80%) and decline to 
(<10%) while CD127+ cells slowly increase their frequency concurrently 13. This phenomenon 
has typically been interpreted as a “selective” loss of KLRG1 (short-live effectors), and a 
preferential survival of CD127 cells. However, it has not been definitively shown, that there is 
not interconversion between these phenotypes in vivo which could alter our interpretation of the 
nature of these cells 13. Two recent studies have given credence to plasticity; the Goldrath group 
has found the transcription factor Id2 expressed in KRLG1+ cells in the memory phase to 
“reinforce” effector differentiation, as deletion of ID2 led to “dedifferentiation” to CD127+ cells 
17. In addition, an elegant use of KLRG1-Cre with fate-mapping led Flavell and co-workers to 
discover CD127+ cells in all phases of effector and memory response to be labelled suggesting a 
time-period of KLRG1 expression 18. Notably, these traced cells were similar to non-traced 
CD127+ cells. An important caveat here is that nearly all cells express KLRG1 to intermediate 
levels very early in the infection, and uniformly downregulate CD127, thus whether KLRG1 
conversion occurs later in the response is unclear.  
 While the heterogeneity in CD8 T cell response to acute infection has been studied in 
relatively great detail, we are now starting to understand the heterogeneity in response to chronic 
viral infection. The generation of “exhausted” T cells that express PD-1 during antigen 
persistence was originally thought to be a monolithic phenenomenon 19. The acquisition of the 
exhausted phenotype correlates well with and is thought to promote viral persistence, although, 




secrete cytokine and mediate cytolysis while also losing ability to proliferation and becoming 
susceptible to apoptosis 20. However, the original idea that cells have lost all function and are 
unable to proliferate were mostly demonstrated ex vivo or in transfer settings. A seminal study by 
the Zehn group demonstrate equivalent, if not enhanced per-cell protection, and proliferative 
capacity by exhausted T cells compared to memory T cells following transfer into T cell 
deficient recipients21 . In addition, an oft forgotten finding is that mice infected with virulent 
LCMV-c13 can control viremia in 60-80 days in a B and T cell dependent manner. Thus, within 
the exhausted population of CD8 T cells exists the capacity to control viral replication and host 
burden.  
 The first indication there could be different functional subsets in chronic LCMV infection 
arose from a study by Wherry and colleagues who found the amount of PD-1 expression on 
antigen-specific T cells could predict expansion following transfer into recipient mice 
{Blackburn:dj} . These results supported the idea of a “terminally exhausted” population and a 
more protected subset of cells which could still be “reinvigorated”. This study was extended with 
the usage of the T-box transcription factors T-bet and Eomes to distinguish between a 
“progenitor-like” and “terminal” subset 22 . Tbethi cells had lower PD-1 expression compared to 
Eomeshi cells. Based on the use of adoptive transfer into naïve an infection matched mice the 
authors developed a model whereby Tbethi cells acted as progeny to Eomeshi cells with both Tbet 
and Eomes expression required for viral control in genetic deletion experiments. However, it 
should be noted that CD8 T cell intrinsic expression of these factors was not clearly shown to be 
required for viral clearance. 
 In addition to the use of T-bet and Eomes expression in understanding T cell dynamics 




exhibits stem-cell like features, in some ways similar to the T-bethi cells6-8 . However, the TCF-
1+ cells have been shown to express high levels of Eomes rather than T-bet suggesting a potential 
hierarchy of heterogeneity more complex than expected8 . The discrepancy between these two 
ideas and a resolution of them is currently lacking.  
 In this section, we first provide a more thorough analysis of the CD8 T cell response to 
LCMV-c13 infection making comparisons at different time points of infection and in the well-
studied context of CD4 depletion. We shed light on the dynamics between these subsets using a 
combination of in vivo BrdU labeling, and genetic lineage tracing. Conceptually we find a 
functional T cell response to likely be driven by both cytokine and antigen-driven dynamics 







Memory CD8 T cell Subsets and Heterogeneity in Homeostatic Turnover 
 We first were interested in a formal analysis using both transcription factor and cell-
surface marker expression of memory T cell subsets and their dynamics following acute LCMV-
Armstrong infection. To this end, we infected Prdm1-YFP reporter mice with LCMV-
Armstrong, and from Day 40-44 administered BrdU in the drinking water (Fig 1A). Analysis of 
splenocytes on Day 44 revealed increased frequency of gp33-tetramer binding CD8 T cells that 
did not express PD-1 indicating a resolved infection (Fig 1B). These cells were uniformly 
CD44hi, however, we noted three unique populations that could be defined using CD62L and 
CD127. Thus, as others have observed there is heterogeneity within the TEM compartment 
(CD62L–) cells (Fig 1B). This compartment can be subdivided by CD127+ and CD127– 
expression; CD127– are almost exclusively KLRG1+ and YFP+. CD127+ is typically correlated 
with long-lived potential so the usage of CD62L+ (TCM) could be functionally irrelevant. We 
noted a very close correspondence between TCF1 expression and CD127 expression. TCF1 is a 
HMG-box transcription factor that promotes memory T cell formation; and is correlated with 
cells that have high proliferative capacity. TCF-1 has been shown to repress Prdm1, however, we 
observed YFP+TCF-1+ cells these cells could also be defined by CD127+KLRG1+ (Fig 1B). 
Thus, a relatively stable intermediate state exists in which both TCF and Prdm1 are expressed 
potentially lending to characteristics of cells expressing each factor by itself.  
 When we analyzed the frequency of BrdU+ within each memory T cell subset, we found 




consistent with homeostatic turnover of this population (Fig 1C). TCF1+YFP+ cells had 
approximately half as much BrdU incorporation, while YFP+TCF1– (KLRG1+CD127–) cells had 
<0.5% BrdU incorporation (Fig 1C). These results suggest that the KLRG1+CD127– population 
is relatively stable at this timepoint, with likely little contribution from other subsets, and low 
overall turnover. Sarkar et al. reported KLRG1+ during the effector phase to have high BrdU 
incorporation, highlighting, a contrast between cell-surface phenotype and proliferation at 
different timepoints 23. Thus, as others have implied, the TCF1+CD127+ likely persists due to 
increased homeostatic turnover. Importantly, whether KLRG1+CD127– cells are intrinsically 
short-lived is unclear. As they do not express CD127, they cannot respond to IL-7 to proliferate, 
and declining amounts of antigen following infection could reflect their loss. Conversely, in the 
presence of antigen, these cells could potentially exhibit increased half-life.  
Identification of heterogeneity within TCF1– subset in chronic viral infection 
 Our analysis of memory T cell heterogeneity prompted us to investigate the heterogeneity 
within exhausted T cells during LCMV-c13 infection. Specifically, we sought to more accurately 
define antigen-specific CD8 T cells by both transcription factor and surface marker expression. 
Genetic deficiency experiments have suggested there to be a potential hierarchy of progenitor 
subsets to maintain the CD8 T cell response which include cells expression T-bet and TCF1. In 
addition the use of the inhibitor receptor Tim-3 expressed on Blimp-1+ cells has identified 
“terminally exhausted” cells. The relationship between these markers, and relationship to PD-1 
expression are not well-defined.  
 To closely examine the heterogeneity in CD8 T cell response, we infected mice with 




viral load is high in the serum. Within gp33-specific CD8 T cells, we confirmed the presence of 
reciprocal T-bethi and Eomeshi subsets (Fig 2A).  In addition, we validated that T-bethi cells 
expressed lower amounts of PD-1 compared to Eomeshi cells. When we analyzed the expression 
of TCF-1 and Tim-3+ we found 3 distinct populations of cells. The TCF-1+Tim-3– and TCF1–
Tim-3+ populations have been previously described, however, we found a substantial fraction of 
cells that were TCF-1–Tim-3– (DN)  (Fig 2B). Unexpectedly, we found DN cells to exhibit the 
lowest expression of PD-1 among the three subsets as defined by TCF-1 and Tim-3. Although, 
we could confirm lower PD-1 expression in TCF-1+ cells compared to Tim-3+ cells (Fig 2B).  
When we examined the expression of T-bet and Eomes within each of these populations we 
noted that the DN fraction has the highest fraction of T-bethi cells while the TCF-1+ population 
had the lowest (Fig 2C). Using these markers, we found T-bethiTCF-1–Tim-3– to have the lowest 
PD-1 expression indicating that a linear expression of PD-1 initiating with the stem-cell like 
TCF-1+ population may not be the case (Fig 2D). These results demonstrate previously 
unappreciated heterogeneity within “exhausted” T cells and beg the question of how these 
subsets are regulated and contribute to viral clearance.   
“Terminally Exhausted” Tim-3+ cells are not-intrinsically short-lived 
 Our analysis confirmed that TCF1–Tim-3+ cells express the highest levels of PD-1 which 
has been associated with a terminally exhausted state incapable of proliferation. For 
approximately 10-15 years following the description of “exhausted” T cells their presence in the 
host was not thought to require significant factors to maintain their presence other than antigen. 
However, now it is currently thought that exhausted cells require continuous replenishment from 
a progenitor pool7,8,22 . This concept implies Tim-3+ cells are inherently prone to cell death, and 




cells lacking expression of T-bet and/or TCF-1 are intrinsically short-lived. These models rely 
upon the use of transfer studies, while illuminating, are subject to caveats of competition with 
endogenous T cells which could confound interpretation of the situation in an endogenous mouse 
when performing genetic experiments. 
 We thus sought to directly test the ability of Tim-3 cells to persist in a host. To this end, 
we first infected mice with LCMV-c13 to establish a persistent infection for 4 weeks. We then 
sorted CD8 T cells expressing PD-1+Tim3+ of PD-1+Tim-3– (including TCF-1+ progenitor cells) 
and transferred ~105  cells into T cell deficient, TCRbd–/– recipients (Fig 3A). The benefit of this 
model is that these mice do not have endogenous T cells which could potentially compete for 
LCMV antigen with transferred cells, allowing us to determine whether Tim-3 cells can persist. 
One day after transfer, we infected mice with LCMV-Armstrong, which established a persistent 
infection, in these immune-incompetent hosts (Fig 3A). As expected, we observed a greater 
expansion of Tim-3–cells compared to Tim-3+ cells by analysis of the PBMC at Day 8 following 
infection (Fig 3, B and C) . However, Tim-3+ cell were present in appreciable frequencies at this 
timepoint (Fig 3, B and C). When we then analyzed recipient mice approximately 3 weeks post-
transfer, we found similar total frequencies of transferred Tim-3+ cells in the recipieints (Fig 3, B 
and C). A caveat of these studies, is that Tim-3+ could be undergoing homeostatic proliferation 
in the lymphopenic environment, rather than direct antigen-induced survival, nevertheless, they 
establish Tim-3+ cells can persist. These data suggest that the assumption that Tim-3+ cells are 
short-lived, and require replenishment from a progenitor pool might need to be revised. 




 Our experiments indicate that Tim-3+ cells could be more resilient that currently thought. 
It is possible Tim-3+ cells possess the ability to proliferate in addition to TCF-1+ cells. Current 
models suggest TCF1+ progenitor cells produce TCF1–Blimp-1+ cells to “sustain” the CD8 T 
cell response. This model is derived from a series of studies which utilized either germline TCF7 
or conditional TCF7 knockouts using CD4-Cre 7,8 . In the setting of TCF7 deficiency the initial 
expansion of CD8 T cells was unaltered with the generation of Tim-3+ cells, however, this 
response is significantly reduced later in the infection (>30 days). Importantly, Shwartzberg and 
colleagues showed that the antigen-specific CD4 T cell response is severely reduced in CD4-Cre 
Tcf7F/F mice potentially indicating a cell-extrinsic effect of TCF7 loss. In support of a cell-
intrinsic role of TCF7 in CD8 T cell maintenance, several groups have performed transfer 
experiments or mixed bone marrow chimeras with WT and TCF7 deficient cells which 
demonstrates a competitive disadvantage of these cells. However, the relevance of these transfer 
experiments to the endogenous T cell response is not extremely clear, as competition with 
endogenous cells is not a factor. 
 While the TCF1+ progenitor cells have been unequivocally shown to produce Tim-3 
progeny and also endowed with the ability to self-renew, the rate of this process is unclear. Their 
stem-cell like features include expression of Kit, Sox4, and Lef, but their proliferative rate 
remains unclear 6 . It is possible that TCF1+ cells are cycling at high rate to replace Tim-3 cells 
or act more similar to LT-HSCs which exhibit quiescence and replenish mature cells more 
slowly 24 25 . In addition, it has not been determined whether Tim-3+ cells also possess the 





 To assess the proliferative dynamics of the TCF1+ and TCF– subsets we analyzed the 
frequency of Ki-67+ cells in each subset in the chronic phase of the infection (~4 weeks 
following infection). Consistent with TCF1+ were  ~5-10% Ki-67+ on Day 22 which was also 
observed for DN cells (Fig 4A). However, Tim-3+cells were ~20-30% Ki-67+ suggesting a 
significantly higher entry into cell cycle (Fig 4A). These results are consistent with the TCF1 
being a quiescent population, unexpectedly, the Tim-3 cells as an effector cell that maintains the 
ability to proliferate in vivo. As Ki-67 is a marker of non-G0 cells, we wished to confirm directly 
if Tim-3+ cells were actively proliferating by assessing BrdU incorporation. We found the 
frequency of BrdU+ cells following 24 hour of 1mg BrdU pulse was similar to Ki67 frequency 
with 20% of Tim-3+ cells and 5% of TCF1+ and DN cells being labelled with BrdU (Fig 4B).  
However, we were concerned that Ki-67+ and BrdU labelled Tim-3+ cells could have 
recently differentiated from the TCF-1+ population over the course of 24 hours and changed their 
phenotype; and thus, are not bona fide Tim-3+ cells but simply recent emigrants from the TCF-1+ 
pool of cells. We thus performed a 2 hour BrdU pulse to assess cell-cycle progression on a time-
scale where cellular phenotype is relatively stable. Our analysis revealed a similar but decreased 
trend with 6-8% of Tim-3+ cells labelled with BrdU with only 2% of TCF-1+ cells labelled (Fig 
4C). These data indicate that Tim-3+ cells actively cycle in vivo and that the TCF-1+ and DN 
cells are relatively quiescent and draw into question the importance of the role of the TCF1+ 
population in sustaining the overall response.  
CD4 T cell deficiency results in altered CD8 T cell subset distribution  
 CD4 T cells have an established role in several viral and tumor contexts. For example, 




is established and CD8 T cells have diminished ex vivo cytokine production, and are so-called 
“helpless” T cells 26. Given the importance of CD4 T cells in directing immune responses we 
wished to perform a direct comparison between CD8 T cell responses in mice sufficient and 
deficient CD4 T cell responses.  
 To this end, we examined the CD8 T cell response in chronic phase of the infection (Day 
15-30) when viral loads are similar between both groups. Importantly, at Day 30 we did not find 
a significant reduction in the absolute number of CD8 T cells or gp33-specific T cells (Fig 5, A, 
B, E). However, when we analyzed the expression of TCF1 and Tim-3 within gp33-specific cells 
we observed an altered distribution of cells in CD4 Depleted mice. Specifically, we observed an 
increase in the frequency of TCF-1+ cells in CD4 depleted mice, and a reduction in the frequency 
of DN cells (Fig 5, B and D). The loss of DN cells suggested to us that expression of T-bet 
would be lost in CD4 depleted mice as the DN subset of cells is substantially enriched for T-bet 
expressing cells. Indeed, when we analyzed the expression of T-bet and Eomes we found an 
almost complete loss of T-bet expressing cells in mice depleted of CD4 T cells (Fig. 5C) . Thus, 
CD4 T cells play a role in the induction of T-bet expression and maintenance of the DN subset in 
CD8 T cells during the chronic phase of LCMV-c13 infection.  
The relative expansion of the TCF-1+ population suggests that CD4 help may be required 
to mobilize this population into TCF-1– effector cells and without their presence results in a 
“build-up” of this population. Importantly, we found an accumulation of Tim-3hi cells in CD4 
depleted mice suggesting their turnover to be reduced (Fig 5, B and D). Thus, in CD4 depletion 
following initial inflammation following the infection, there is an accumulation of Tim-3+ cells 




CX3CR1 marks a subset of exhausted DN cells that express T-bet 
Our results from CD4 depletion indicated that a previously uncharacterized population of 
antigen-specific cells (double negative, TCF-1–Tim-3–) was severely reduced compared to 
control mice.  We wished to further characterize this population to determine its function and 
relevance to CD8 T cell turnover during chronic viral infection. To assist in our studies, we 
wished to find a cell-surface marker which we could use as a tool to investigate the nature of 
these cells. An important consideration would to be find a marker that would only be expressed 
in TCF1– (Blimp-1+) population of cells. Given that DN cells were enriched for T-bet expressing 
cells, we analyzed the expression of genes that are T-bet dependent in effector CD8 T cells form 
acute viral infection.  
Specifically, we focused on both KLRG1 and CX3CR1, both well-characterized genes to 
be T-bet dependent. A previous study using the Cx3cr1gfp/+ reporter mouse reported ~40% of 
gp33-specific cells to express cx3cr1 at Day 40 after infection and claimed these cells were 
memory counterparts in chronic infection. We first examined expression of CX3CR1 and 
KLRG1 on PD-1 expression CD8 T cells 4 weeks following LCMV-c13 infection.We found 
approximately 20% of PD-1+ to express CX3CR1, and approximately 5% to express KLRG1. 
Notably, KLRG1+ cells were almost exclusively CX3CR1hi (Fig 6A).  In acute viral infection 
KLRG1 and CX3CR1 expression are very well correlated, however, in chronic viral infection 
KLRG1 expression is only restricted to a small subset of CX3CR1 expression (Fig 6A). As an 
additional validation of CX3CR1 expression on exhausted CD8 T cells we utilized  Cx3cr1gfp/+ 
reporter mice. Two weeks following LCMV-c13 infection we detected GFP expression in PD-1+ 
cells from PBMC with a subset of these cells staining positive with CX3CR1 antibody (Fig 6B). 




exclusively found in YFP+ cells in both the Tim-3 positive and negative compartment (Fig 6C). 
This result contrasts with the idea that CX3CR1 marks “memory-like” cells in chronic viral 
infection as TCF-1+ cells did not express CX3CR1. Thus, similar to other cell-surface molecules 
such as Tim-3, and 2B4, CX3CR1 is almost exclusively expressed on TCF1lo cells, however its 
expression pattern varied.  
Given the readily detectable CX3CR1 expression, we decided to focus on further analysis 
of CX3CR1 expression during chronic viral infection. We first performed a more in-depth 
analysis examining CX3CR1 expression and its relation to exhaustion-related transcription 
factors and cell surface molecules. When we analyzed mice on Day 22 following LCMV-c13 
infection we found CX3CR1 expression to be heavily enriched in both DN (TCF-1–Tim3–) and 
Tim-3+ cells and relatively sparse within TCF-1+ cells, similar to results obtained with Prdm1-
YFP reporter mice (Fig 7, A to C). We noted a direct correlation between CX3CR1 expression 
and T-bet expression as expected (Fig 7C). Using Tim-3 and CX3CR1 we were able to define a 
population of cells, TCF-1–Tim-3–CX3CR1+ that were almost exclusively T-bethi.  
We next were interested in determining whether CX3CR1 cells were enriched for a 
population of cells that were quiescent or actively proliferating. On Day 21 of LCMV-c13 
infection we treated mice intraperitoneally with 1 mg of BrdU twice over the course of 24 hours, 
and analyzed mice immediately after. When we analyzed gp276-specific cells on Day 22, we 
found CX3CR1+Tim-3+ cells to exhibit the highest amount of BrdU labelling ~35%. 
CX3CR1+Tim-3– cells that are T-bethi had similar BrdU incorporation to CX3CR1–Tim-3+ cells 
(Fig 8, A and B). Interestingly, the CX3CR1– DN population had the lowest BrdU incorporation 




proliferative population of cells which likely reflects proper mobilization and turnover of the 
CD8 T cell response facilitating viral clearance.   
To assess the proliferative rate over several days during the chronic phase of LCMV-c13 
infection we performed sequential BrdU pulse followed by an EdU pulse. We hypothesized cells 
incorporating BrdU would also incorporate EdU and a majority of cells would be dual-labelled. 
However, we found only a third of BrdU+ cells were also labelled with EdU+ suggesting 
intermittent periods of proliferation and quiescience within the PD-1+ population (Fig 8C). In 
addition we found EdU+BrdU– cells  over this time period indicating quiescence and entry into 
cell-cycle over 2-3 days. When we used CX3CR1 or KLRG1 to determine if there was 
enrichment for a given labelled population we did not note any differences (Fig 8C). These 
results suggest relatively desynchronized proliferation within the exhausted T cell compartment, 
with each cell engaging cell-cycle periodically. It remains to be determined what signals regulate 
entry into cell-cycle or whether it is simply a passive process.  
IL-21 deficiency results in loss of CX3CR1+ cells and defective viral control 
 The high proliferative rate of CX3CR1 expressing cells suggested that this subset could 
be vital for eventual viral control. Given that this CX3CR1 is enriched in the DN population, we 
first asked whether CX3CR1 cells were diminished in CD4 depleted mice which could partially 
account for the lack of viral control. Indeed, when we analyzed CX3CR1 expression on Day 30 
of infection we found a severe depletion of CX3CR1 expressing cells within the TCF1– pool of 
gp33-specific cells (Fig 9A). Thus, CD4 help maintains the presence of a highly proliferative 




 We were next interested in determining how CD4 T cells promote the generation of T-bet 
expressing CX3CR1 cells. IL-21 produced heavily by CD4 T cells is a critical factor required for 
viral clearance following LCMV-c13 infection. While IL-21R is expressed on many lymphoid 
cell types,  several reports have reported a cell-intrinsic role for IL-21 signaling in 
“maintenance” of a CD8 T cell response. We thus hypothesize IL-21 signaling could promote the 
the generation and/or maintenance of CXCR1 expressing exhausted T cell cells.  
 To this end we first infected WT and IL-21R deficient animals with LCMV-c13, and 
validated a complete lack of LCMV-c13 clearance from the serum of mice 80 days following 
initial infection (Fig 9B). When we analyzed mice 30 days after infection when viral titers are 
similar between WT and IL21R KO, we first noted increased splenocyte numbers in IL-21R KO 
mice (Fig 9C). This result was not previously reported, but was very robust in our hands. When 
we analyzed gp33-specific CD8 T cells we found there to be a reduced frequency in the spleen, 
but given larger spleen size, we did not find an absolute reduction of gp33-specific cells in the 
spleen (Fig 9, D and E). However, when we measured CX3CR1 expressing cells within the 
gp33-specific compartment, we found a similar reduction but with less severity in IL-21R 
deficient mice compared to CD4 depletion alone (Fig 9, D and E). Thus IL-21 produced by CD4 
T cells likely promotes the maintenance of a CX3CR1+ population of proliferating antigen-






 Herein we provide a detailed cellular evaluation of the CD8 T cell response to chronic 
viral infection. Specifically, we closely analyze the proliferative dynamics directly ex vivo using 
a combination of proliferative markers and BrdU incorporation. These results indicated 
previously underappreciated ongoing proliferation within the “exhausted” T cells. Moreover, we 
find the so-called “terminally exhausted” subset of Tim-3+ cells to exhibit the highest in vivo 
proliferation. These data potentially indicate a need to revise our current conceptualization of 
exhausted T cells.  
 Much of the knowledge we have concerning the function of exhausted T cells has come 
from both ex vivo stimulation and/or transfer studies. These data have revealed poor cytokine 
production and proliferation in vitro compared to effector cells in acute infection. In addition, 
they have been thought to exhibit poor persistence in naïve mice relative to memory cells 
generated after acute infection. However, more recently, these concepts have needed significant 
revision. Zehn and colleagues were able to show proliferative capacity and protection provided 
to immune-deficient mice by exhausted T cells at a comparable level to memory T cells 21. In 
addition significant numbers of exhausted cells persisted in naïve mice for over 50 days and were 
detectable after recall challenge 21.   
 These data have strengthened the view that a subset of cells “maintains” protective 
capacity in chronic infection. TCF-1 expressing cells exhibit proliferative capacity and self-
renewal upon transfer thus fulfilling this role 6,8. However, a distinction must be made between 
proliferative capacity and in vivo proliferation. Our results show that in vivo proliferation in the 




TCF1– cells, specifically CX3CR1+Tim-3+ cells. These data are reminiscent of results obtained 
from transfer studies examining contribution of HSCs to hematopoiesis. The generation of bone 
marrow chimeras involving transfer of HSCs into irradiated mice induces an “emergency” 
hematopoiesis scenario that strongly promotes HSC proliferation to fill the cellular niche 27. 
However, direct measurements of hematopoiesis in steady-state animals have revealed much 
lower contribution to mature subsets 24,25. It appears this process is carried out by downstream 
progenitor cells which exhibit high proliferative rates 24,25.  
 Our results support a stem-cell like role for TCF-1+ cells, however, where exactly on the 
hierarchy of cells this subset exists is unclear. We detected similarly low levels of turnover 
within TCF1–Tim3– CX3CR1+(T-bethi)  and CX3CR1–compartments as previously published 22. 
While both loss of TCF1 and T-bet in the germline promote viral persistence the cell-intrinsic 
role for these factors in the CD8 T cell response remain to be determined as they are expressed in 
several other immune lineages. Importantly, the ability to maintain quiescence is correlated with 
an enhanced “recall” proliferation in transfer environments. We do not have a clear explanation 
as to the mechanistic basis underlying differences in transfer-induced proliferation following 
infection of a recipient compared to proliferation well-into persistent antigen. We suspect this 
could be do with mimicking conditions of T cell priming following infection that are more 
conducive for quiescent cells, such as naïve T cells.  
 An important question that remains is what extrinsic factors regulate CD8 T cell 
dynamics during persistent infection. We have identified CD4 help to be a critical factor in 
maintaining the CX3CR1+ subset of T-bet expressing cells, in part through production of IL-21. 
Interestingly, in both of these scenarios we do not observe a reduction in antigen-specific CD8 T 




we propose could be a functional readout of exhaustion. We hypothesize this to be the case as the 
generation of Tim-3+ cells and decreased cytokine production is observed very early in the 
response to LCMV-c13 7,28. However, generally CD8 T cells can still mediate clearance of virus. 
Thus, under conditions of high viral load “exhausted” cells will generally be present, however, 
their functional capacity in reducing viral load is likely determined by the extent to which 






4.5 MATERIALS AND METHODS 
Please see Section 3.5 for a list of overlapping Materials and Methods.  
Mice 
IL21r–/–, Prdm1-YFP, Cx3cr1gfp/+ were obtained from Jackson laboratories. TCRbd–/– 
were bred in house.  
Cell Sorting and Transfer 
 CD8 T cells were pre-enriched using Flow Comp Dynabeads (Thermo Fisher) followed 
by sorting on an Aria-III (BD). Sorted cells were transferred intravenously into recipient mice at 
the indicated cell numbers.  
Antibody Treatments 
a-CD4 (GK1.5, Leinco) was injected at a dose of 200µg intraperitoneally on Day –1 and 
+1 of LCM-c13 infection.  
BrdU and EdU Labeling and Detection 
 BrdU (Sigma) or EdU (Cayman) was administered i.p. at a dose of 1 mg to mice which 
were sacrificed at the indicated time-points. Cells were processed using aAPC BrdU Flow Kit 
(BD Pharmingen) and a Click-iT Plus EdU Pacific Blue Flow Cytometry Kit (Invitrogen). BrdU 
was detected using an AF647-conjugated anti-BrdU(MoBU-1, Invitrogen) antibody for dual 
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Figure 4.1. TCF1+Blimp-1– subset of Memory T cells exhibit highest amount of homeostatic 
proliferation. (A) Schematic of BrdU labelling experiment of Prdm1-YFP mice infected with 
acute LCMV-Armstrong. (B) Flow Cytometry measuring expression of indicated proteins or 
binding of tetramer from mice in A. (C) BrdU incorporation in indicated memory populations 






Figure 4.2. Resolution of TCF-1, T-bet, and Eomes expression in Exhausted T cell subsets. 
(A-D) Flow cytometry measuring expressing of indicated proteins or tetramer binding in on Day 
30 in splenocytes from mice infected with LCMV-c13. Data are representative of >20 mice over 






Figure 4.3. PD-1+Tim-3+ cells are able to persist in competition-free host with persistent 
antigen. (A) Schematic of experiment (B) Flow cytometry analysis measuring frequency of 
Cd8b expressing cells in PBMC in TCRbd–/– at indicated times following LCMV-Armstrong 
infection. (C) Quantification of B. Each symbol represents an individual mouse; small horizontal 






Figure 4.4. Increased Ki-67+ and BrdU labelling within Tim-3+ cells during chronic phase 
of LCMV-c13 infection. (A-C) Analysis of gp33-specific CD8 T cells 4 weeks after LCMV-c13 
infection of WT mice examining expression of Ki-67 (A), BrdU incorporation following a 24 
pulse (B), and a 2 hour pulse (C). Each symbol represents an individual mouse; small horizontal 






Figure 4.5. Lack of CD4 T cell help results in loss of TCF-1–Tim-3– (DN) and T-bet 
expression in antigen-specific CD8 T cells on Day 30. (A) Absolute number of splenocytes on 
Day 30 following LCMV-c13 infection of WT mice. (B, C) Flow cytometry measuring 
expression of indicated proteins or tetramer binding in splenocytes. (D, E) Frequency (D) and 
absolute number (E) from B. Each symbol represents an individual mouse; small horizontal lines 





Figure 4.6. CX3CR1 is expressed in exhausted PD-1+ cells almost exclusively within Blimp-
1+ cells. (A-C) Flow cytometry measuring expression of indicated molecules in splenocytes 
following LCMV-c13 infection on Day 28 (A). (B) Analysis of CX3CR1 expression in PBMC in 
Cx3cr1gfp/+ mice infected with LCMV-c13 on Day 14. (C) Flow cytometry measuring expression 







Figure 4.7. CX3CR1 expression is restricted to TCF1– cells and correlated with expression 
of T-bet in exhausted CD8 T cells. (A-D) Flow cytometry measuring expressing of indicated 
proteins or tetramer binding in on Day 22 in splenocytes from mice infected with LCMV-c13. 







Figure 4.8. CX3CR1+Tim-3+TCF-1– cells are most actively engaged in cell-cycle and exhibit 
desynchronized proliferation. WT mice were infected with LCMV-c13 and subject to a 24 
hour BrdU pulse. (A,B) Flow cytometry measuring expressing of indicated proteins or tetramer 
binding in splenocytes on Day 22 (A) and assessment of BrdU incorporation in indicated subets 
(B). (C) (Top) Schematic of BrdU and EdU sequential labeling 4 weeks following infection 







Figure 4.9. IL-21 deficiency results in loss of CX3CR1 expressing cells in chronic phase of 
LCMV-c13 infection and is correlated with loss of viral control. (A) Flow cytometry 
measuring expressing of indicated proteins or tetramer binding in splenocytes on Day 30 of 
LCMv-c13 infection. (B) Viral load on Day 80 of LCMV-c13 infection as measured by qPCR of 
LCMVgp transcript. (C-E) Analysis of Il21r–/– mice following infection with LCMV-c13 on Day 
30 of infection. (C) Absolute number of splenocytes. (D-E) Flow cytometry measuring 
expressing of indicated proteins or tetramer binding in splenocytes on Day 30 of LCMv-c13 

















 In this work, we have sought to dissect signaling mechanisms within the adaptive 
immune system. In Chapter 2, we focus on understanding the role of the adaptor molecule 
CD2AP, and find that it regulates TCR signaling in CD4 T cells, and modulates TFH 
differentiation during chronic viral infection. Loss of CD2AP enhances the germinal center 
response and generation of neutralizing antibodies which facilitate clearance of chronic viral 
infection. In Chapter 3 and 4, we turned our attention toward CD8 T cells and their role in both 
viral control and host damage. We describe a pivotal role for PD-1 in promoting immune 
homeostasis and generation of a durable immune response. We further define this function to be 
of significance in the context of Type I Interferon highlighting the need to consider 
microenvironmental factors in checkpoint blockade. Finally, we reassessed conventional views 
regarding the CD8 T cell response and took a close look at cell turnover. Our studies shed light 
on novel subset of “exhausted” T cells that correlates well with an enduring immune response. 
 The immune system is relatively unique as it exists in a state of relative quiescence until 
certain signals are received which rapidly mobilizes effector functions of tissue and cells. These 
signals are initiated by recognition relatively conserved molecular patterns among fungi, 
bacteria, and viruses by the innate immune system. However, the adaptive immune system, is 
able to recognize all potential molecular moieties that are unique to each pathogen – the central 
function of the TCR and BCR. Thus, a central question in adaptive immunity is mechanisms 
underlying and regulating T and B cell function in the integrated environment of the host. 
Ultimately, these signals are transduced into global transcriptional and epigenetic changes that 
may become “fixed” and define lineages. However, a substantial body of evidence indicates that 




significantly alter the ensuing response giving credence to continued plasticity of the immune 
response1-3.  
 While many of the central signaling molecules that are involved in signal transduction in 
T and B cells are known, how this network is modulated in the context of an in vivo immune 
response is under-studied. Our work, have revealed how the signaling adaptor CD2AP can 
modulate TFH likely through modulation of TCR signals. It is unclear whether this is the sole 
function of CD2AP in CD4 T cells, or whether it also plays a role in modulating other signaling 
pathways in TFH differentiation which is then finally integrated with TCR signals. The concept 
that modulation and strength of TCR signal influences TFH development and maintenance has 
emerged over the past several years 4,5 6. However, whether intracellular signaling modules can 
influence the TCR independent of TCR affinity for antigen is not as clear. It will be interesting to 
determine the extent to which accessory molecules can be induced and/or regulated to ultimately 
control the functions of T cells. Importantly, we find a potentially opposite role for the related 
CMS-family member CIN85 in the response to LCMV-c13 infection. While we did not formally 
demonstrate TFH differences we did find evidence of diminished neutralizing antibodies in CIN85 
deficient mice. Further analysis will be required to delineate the role of CIN85 in CD4 T cells. A 
previous report has implicated CIN85 in regulation TGF-b signaling via recycling of TGF-bRI to 
the cell surface; this could play a role in T cells in modulating TFH function 7.  
 Notably, we did not observe consistently enhanced TFH differentiation in all 
immunization contexts. We do not have a sufficient explanation for the underlying mechanism 
behind this phenomenon. However, a previous report, described similar behavior of DENND1b 




provocative, but speculative, explanation could lie in the assembly of other molecules in a cell-
type specific manner that ultimately directs the function of individual signaling proteins.  
 Both in vitro and most in vivo studies initiate TCR signal transduction in a strong single 
bolus either through crosslinking antibodies, bolus peptide, or acute infection. These types of 
experiments provide a certain kind of stimulation to the TCR that can be assayed by proliferation 
or direct ex vivo cytokine production. However, the nature of T cells in providing protection to 
the host likely occur under different scenarios of weak but continued stimulation occurring over 
a time-line of days to weeks to months. The function of T cells in the clearance of acute 
pathogens is also not abundantly clear with significant control exerted by T cells only well-
described in chronic viral infections or cancer 9 10 11 12 . Thus, a potentially important and under-
developed area of research is understanding the modulation of TCR signal transduction in a 
variety of contexts especially involving persistent stimulation.  
 Chronic viral infections and developed tumors provide persistent antigen stimulation to T 
cells. As a surrogate marker, PD-1 expression, can identify cells with ongoing TCR signaling 13 . 
PD-1 is expressed by both CD4+ and CD8+ T cells, and in these persistent antigen contexts, a 
commonly held view is that these cells are dysfunctional 14 . However, more recently, this idea 
has come under scrutiny with the following developments. CD4 T cells simply alter their 
cytokine profile to facilitate a more productive immune response; specifically IL-2 production is 
exchanged for IL-21 production 15 . CD8 T cells that are “exhausted” have been demonstrated to 
show excellent activity when transferred into permissive environments 16 . Thus, the notion that 




 Our studies investigating the major negative regulator of T cell function, PD-1 in chronic 
LCMV infection, have revealed a pivotal role for PD-1 in promoting a durable adaptive immune 
response. At a mechanistic level, the previously described functions of PD-1 in preventing lethal 
immunopathology hold, but the ultimate consequences of tissue damage appear to depend on the 
context within the infection. These results also indicate that “more” is not necessarily better for 
control of virus. Blockade of PD-L1 at early time points of infection clearly result in exaggerated 
CD8 T cell responses, but have almost no impact on viral control, and instead simply promote 
damage. While it is hard to negative effects of damage on other arms of the immune system and 
an enhanced CD8 T cell response, the idea that CD8 T cells mediate a significant impact on viral 
clearance has not been well-established. The function of CD4+ T cells and B cells in production 
of neutralizing antibodies likely has a stronger role, with CD8 T cells acting to promote 
elimination of reservoirs of virus.  
 A common theme in the immune system is how the cytokine milieu ultimately directs 
immune responses. We have shown how Type I Interferon can modulate the ultimate effect of 
PD-1 blockade in the host. While the mechanistic basis for this effect is unclear, the implications 
are provocative. Notably, while we observe an effect on the CD8 T cell response in settings of 
IFNAR deficiency it is possible effects on other hematopoietic or non-hematopoietic cells 
contribute to the phenotype. Thus, one way in which to modulate the physiologic consequences 
of PD-1 blockade maybe to selectively target cytokine pathways in different cell types to either 
promote or diminish the effect of CD8 T cells on each tissue. While Type I Interferon has been 
proposed a “signal 3” for CD8 T cell activation, recent reports indicate it induces inhibitory 
ligands for NK cells to prevent killing in vivo17 . Given the relative redundancy of co-stimulatory 




enhanced CD8 T cell function via co-stimulation with agonistic TNFR superfamily or B7 
antibodies.  
 The concept that “exhausted” T cells lose proliferative potential and are susceptible to 
apoptosis intrinsically needs significant revision 18 . The discovery of stem-cell like population 
within PD-1 expressing cells with robust proliferative capacity and self-renewal draw into 
question the use of the term “dysregulated”. The so-called “terminal” Blimp-1+ cells in chronic 
have decreased proliferative capacity in transfer settings, however, the relevance of this 
phenomenon in in vivo responses is unclear. These cells possess the higher BrdU incorporation 
and frequency of Ki-67+ cells than the stem-cell like population with proliferative capacity.  
 We propose an altered view of the T cell response to persistent antigen. Antigen 
abundance generally provides a sufficient survival signal to cells such that even Blimp-1+ cells 
remain. However, we rather focus on “dynamics” and continued proliferation as determining the 
extent of “exhaustion”. Specifically the loss of the cytokine and co-stimulatory milieu provided 
by other cells such CD4+ T cells and B cells alter the nature of the CD8 T cell response. This 
results in the presence of “old” cells that are not continually replaced to facilitate a durable 
immune response. A key question that remains is what do we mean by “old” cells –– and 
whether these cells could be considered truly intrinsically dysfunctional. We suspect this could 
be the case, but another interpretation would be “old” cells upregulate numerous co-inhibitory 
receptors that effectively suppress effector signaling to levels that are not physiologically 
relevant for control of virus or tumor. Further work will need to be done to assess whether this 
model is a useful way to think of the T cell “exhaustion”. The generation of tools to effectively 
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